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ABSTRACT

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
MODULATOR THERAPIES IN CYSTIC FIBROSIS: A RETROSPECTIVE
EVALUATION OF A NATIONWIDE SPECIALTY PHARMACY DATABASE

By
Zumi Mehta
May 2020

Dissertation Supervised By Dr. Khalid Kamal
Background: Cystic fibrosis (CF) is a progressive, genetic disorder caused by a mutation
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with
CF experience excessive mucus build up and infections leading to complications in the
pancreas, lungs, and other organs. There has been a paradigm shift in the treatment of CF
with the introduction of CFTR modulator therapies and given their high acquisition cost,
assessing their economic burden along with the adherence rate of patients is imperative.
Objective: (i) To assess the utilization of CFTR modulator therapies in a specialty
pharmacy CF patient population and (ii) to calculate the economic burden of CFTR
modulator therapies and medications utilized for other comorbidities in the CF
population.
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Methods: A retrospective data analysis was conducted using refill and patient assessment
data for CF Patients using CFTR modulator therapies from AllianceRx Walgreens
specialty pharmacy. The study was conducted in two phases. In Phase I adherence was
calculated using Proportion of Days Covered (PDC) measurement and data from the
specialty pharmacy patient assessments focusing on discontinuations, missed doses, and
medication-related adverse events were extracted and analyzed. In Phase II economic
burden was assessed by calculating the spending of the specialty pharmacy on CFTR
modulator therapies, average co-pay of the patients for CFTR modulator therapies and
the cost of other medications reported by the patients (except CFTR modulator therapies)
related to symptom management of CF as well as unrelated to CF. All statistical analyses
were conducted using Statistical Analysis System University Edition (SAS Institute;
Cary, NC).
Result: A total of 4,444 patients contributed to 57,960 refills of CFTR modulator
therapies from January 2015 to August 2018. The overall PDC calculated for the entire
study period for all CFTR modulator therapies was 0.83. Based on the patient assessment
data, majority of the patients reported not missing a dose (n=38,428, 93%), switching as
the most common reason for discontinuing therapy (n=185, 74.9%), and no adverse
events for all three CFTR modulator therapies (n=23,888, 85-95%). A non-linear trend
was observed in patient co-pays with a high of $312.70 (2018) and a low of $182.05
(2016). Patients on primary government insurance had a lower co-pay ($0-$40) compared
to those on commercial insurance ($20-$310). The annual spending of the specialty
pharmacy increased from 2015 to 2018 for all three CFTR modulator therapies. The most
widely reported therapeutic classes for other medications included anti-infectives
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(n=2472, 22.81%), respiratory (n=2192, 20.23%), and electrolytes and dietary
supplements (n=1701, 15.69%). The costs ranged from $0.2-$98,175 for all the other
medications reported by the patients.
Conclusion: Patients with CF demonstrated good adherence to CFTR modulator
therapies. Additionally, patients reported low missing doses or adverse events, all of
which could be attributed to the specialty CF pharmacy program. Also, there seems to be
a substantial economic burden associated with CFTR modulator therapies and other
medications.
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CHAPTER 1: BACKGROUND
INTRODUCTION
Cystic fibrosis (CF) is a progressive, genetic disease that affects the secretory
glands, which make mucus and sweat.1 Mucus is also produced by tissues that line
several organs such as the lungs and nose. The function of mucus is to keep the linings of
these organs moist and prevent them from drying or getting infected. In CF, the mucus
becomes thick and sticky and overtime, it can build up in the lungs resulting in blocking
of the airways and subsequent respiration difficulties. The buildup of mucus in the
respiratory tract also provides an ideal breeding ground for bacteria and fungi, which can
lead to repeated, serious lung infections and can cause severe lung damage over time
(Refer Figure 1).
In addition to lungs, CF affects other organs such as pancreas, liver, intestines,
sinuses, and sex organs. In the pancreas, the thick and sticky mucus causes blockage of
tubes or ducts, which leads to digestive issues as the enzymes produced by pancreas are
blocked from reaching the small intestine. Due to the lack of enzymes, there is no break
down and/or absorption of food, resulting in vitamin deficiency and malnutrition. Further,
patients with CF also suffer from bulky stools, intestinal gas, swollen belly (from severe
constipation), and pain or discomfort.
Another disease characteristic is that the sweat of a patient becomes very salty.
This can lead to an excessive loss of minerals, which upsets the salt and water and causes
further health complications. These complications include dehydration, increased heart
rate, fatigue, weakness, decreased blood pressure, heat stroke, and, in rare instances,
death. It also increases the risk of diabetes, osteoporosis, and osteopenia in patients with

1

Figure 1: Healthy Lung vs CF affected lung

Source: Mayoclinic.org 2
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CF. Problems related to reproductive organs are also common amongst patients suffering
from CF (Refer Figure 2).3

Disease Inheritance
CF is a life-limiting rare genetic disease with autosomal recessive inheritance
associated with “CF-causing” mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) protein. CFTR protein is responsible for regulating the
flow of salt and fluids in and out of the cells in the body. Mutations in the CFTR gene
causes the CFTR protein to malfunction or not be produced at all, which results in a
series of complications in a number of organs including lung infections and destruction of
the pancreas.
CF is also classified as a recessive genetic disease which means that that two copies
of the mutated CFTR gene are necessary to have CF, one inherited from the mother, and
one from the father. Figure 3 provides a summary of the inheritance pattern of CF. If an
individual has a mutation in only one copy of the CFTR gene, he or she does not have CF
and instead is considered a CF carrier. CF carriers can pass their copy of the CFTR gene
mutation to their children. When two CF carriers have a child together, the chances of a
child having CF can vary from 25-50%, as discussed below 4,5 :


25 percent (1 in 4) the child will have CF



50 percent (1 in 2) the child will be a carrier but will not have CF



25 percent (1 in 4) the child will not be a carrier of the gene and will not have CF

3

Figure 2: Organs affected by CF

Source: Cfmedicine.com 6

4

Figure 3: Inheritance pattern of CF

Source: CF Genetics: The Basics 5
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Individuals with CF can also pass copies of their CFTR gene mutations to their children.
If someone with CF has a child with a CF carrier, the chances are:


50 percent (1 in 2) the child will have CF



50 percent (1 in 2) the child will be a carrier but will not have CF
More than 1,500 CFTR mutations have been identified and over 100 mutations

have been shown to cause varying degree of disease severity. These mutations have been
grouped into six classes (Refer Table 1). The five most common mutations that affect
more than 95% of CF population in the United States (US) are:


F508del (86.7% of individuals with CF, Class II mutation),



G542X (4.6%, Class I),



G551D (4.3%, Class III),



R117H (2.7%, Class IV),



N1303K (2.5%, Class II).7
Because not all parents carry identical mutations, a child may therefore, inherit

different mutations from each parent resulting in differential impact on the CFTR protein.
This is one of the reasons why a spectrum of the disease phenotypes is observed.
Additionally, some mutations may only demonstrate a partial effect, which may only
create a CF phenotype when identified in concert with other specific mutations. This
complexity coupled with over 1,800 identified mutations in the CFTR gene produces a
wide variability of effect that affects both the protein function and also the clinical
phenotype.
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Table 1: Various classes of mutations with their primary defects and the outcomes
Mutation
Class
I

Defect

Outcome

Protein production

II

Protein processing

III

Protein regulation

IV

Protein conduction

Complete absence of CFTR
protein due to premature
mRNA terminal (nonsense or
frame shift mutation)
Inability of protein to localize
to correct cellular location due
to abnormal post-translational
modifications
Decreased activity of protein
(chloride channel) in response
to ATP due to abnormalities of
the nuclear binding fold regions
Frequency of flow of ions and
channel opening duration are
reduced though there is
generation of chloride currents
on stimulation with cAMP
Stability of mRNA and/or
mature protein is compromised

V

Reduced amount
of functional
CFTR
VI
Normal amount of
functional CFTR
Source: Rafeeq et al., 2017 8

Enhanced turnover due to Cterminus abnormalities
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Common
mutations
G542X,
W1282X,
R553X,
621+G>T
F580del,
N1303K, A455E
G551D

R117H

A455E
Q1412X

DIAGNOSIS
Unlike other diseases which allow prompt and accurate diagnosis, CF presents
several diagnostic challenges. However, with the advent of sweat chloride testing and
more recently, the newborn screening (NBS), accurate diagnosis of CF is becoming more
practical.
In 1996, the CF Foundation convened a panel of experts to develop criteria for the
diagnosis of CF (Refer Figure 4). The panel’s consensus was that the diagnosis of CF
should be based on the presence of one or more characteristic clinical features, a history
of CF in sibling, or a positive NBS test including laboratory evidence of an abnormality
in the CFTR gene or protein. Acceptable laboratory evidence of a CFTR abnormality
included biological evidence of channel dysfunction (i.e., abnormal sweat chloride
concentration or nasal potential difference) or identification of a CF disease-causing
mutation in each copy of the CFTR gene. The evidence of CFTR abnormality is
necessary since the NBS test is just a screening that identifies individuals at risk for CF.
Positive NBS should be followed by a sweat chloride test to confirm a CF diagnosis. 9,10
NBS for CF is usually done in the first few days after birth as early diagnosis of CF helps
in the prevention of serious lifelong health problems. In NBS, a blood test is conducted to
check the levels of a chemical made by the pancreas called immunoreactive trypsinogen
(IRT). Usually, IRT levels are low in individuals without CF. However, individuals with
CF tend to have high (> 55 ng/mL) IRT levels. Because IRT levels can also be high in
premature birth, stressful delivery, or due to other reasons, DNA test is utilized to check
for mutations or changes in the CF gene. Even with the DNA test, NBS is only a
screening tool and for an actual diagnosis, a sweat test, considered the gold standard for

8

Figure 4: CF Foundation recommended diagnostic process for screening newborns

Source: Farrell et al., 2016 10
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confirming the diagnosis, must be performed.11 This test measures the amount of chloride
(a component of salt) in the sweat since individuals with CF have more chloride in their
sweat than those without CF. If a sweat test is done correctly, then results that are
positive will show a high chloride level. A chloride level of less than or equal to 29
mmol/L signifies that CF is unlikely regardless of age. Repeated testing is needed when
individuals have chloride levels between 30 - 59 mmol/L and those with chloride levels
greater than or equal to 60 mmol/L are likely to be diagnosed with CF. Appropriate sweat
chloride testing is crucial for the diagnosis of CF and CF Foundation requires the testing
to be conducted at accredited CF centers.12

SYMPTOMS OF CF
The symptoms of CF and symptom severity vary from individual to individual.
Some children may start showing symptoms at birth while some may not show symptoms
for weeks, months or even years. The symptoms are broadly categorized into symptoms
of the respiratory tract and other symptoms.

Symptoms of the respiratory tract:13


Chronic coughing (dry or coughing up mucus)



Recurring chest colds



Wheezing (that may not respond to standard asthma therapy)



Shortness of breath



Frequent sinus infections



Allergies that last all year



Recurrent lung infections
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Other symptoms:14


Frequent large, greasy, and foul-smelling bowel movements



Inability to gain weight despite being hungry all of the time



Poor growth



Constipation and intestinal blockage



Recurrent inflammation of the pancreas (pancreatitis)



Symptoms of high blood sugar, such as being thirsty and urinating frequently



Gallstones



Excessive sweating



Salty-tasting skin

TREATMENT OF CF
Currently, there is no cure available for CF and most treatments generally aid in
reducing symptoms and CF-related complications. The management of CF is complicated
as it involves the treatment of a myriad of symptoms. Normally, a multidisciplinary team
of healthcare professionals deliver treatments to keep the lungs clear, prevent or fight
infections, and provide adequate nutrition.

Airway clearance technique
Airway clearance techniques (ACTs) loosen thick, sticky mucus so it can be
cleared from the lungs by coughing or huffing. Clearing the airways may help in
decreasing lung infections and improving lung function. This can be done using manual
chest physiotherapy or a device called the Vest. This jacket shakes the mucus in the
airways, enabling the patient to cough it up. Another portable device is called a "flutter."

11

This causes the mucus in the airways to vibrate or "flutter" when a patient breathes
through the device.15,16

Medications
 Antibiotics
The buildup of thick, sticky mucus in the lungs makes individuals with CF more
susceptible to bacterial infections that can last for short periods of time (acute infections
or exacerbations) or for many years. Antibiotics are recommended to be taken regularly
by patients to keep these infections in check. In serious cases, individuals with CF may
receive intravenous (IV) antibiotics in addition to inhaled or oral antibiotics. Some
examples of these drugs include ciprofloxacin, tobramycin, cephalexin, azithromycin,
and amoxicillin. 17,18

 Anti-inflammatory agents
Inflammation plays a major role in the pathophysiology of lung disease in CF. This
response is primarily triggered as a reaction to the inability of the affected lung to resist
the invasion of the common bacterial pathogens commonly seen in CF. Various antiinflammatory treatment modalities have been tested to be used in CF. Oral corticosteroids
are effective but associated with significant long-term side effects whereas inhaled
corticosteroids are so far not proven to be effective mostly due to the difficulty with their
absorption through the viscid surface secretions of the lung. Also, ibuprofen is potentially
effective but limited because of the need to monitor drug levels and due to its
potential gastrointestinal side effects. Currently, the most promising agents are macrolide
antibiotics such as azithromycin, which possess long-term anti-inflammatory effect and
an excellent safety profile. 18,19

12

 Bronchodilators
Bronchodilators widen the airways by helping the surrounding muscles to relax. This
allows more air to travel through the airways, which ultimately help other medications to
work more effectively. Bronchodilators can be taken before other treatments such as
mucus thinners, airway clearance techniques and antibiotics. Some commonly used
bronchodilators include albuterol and levalbuterol hydrochloride, which can be
administered using metered dose inhaler, nebulizers or dry powder inhalers. 20

 Mucus thinners
Because the primary physiologic manifestation of CF in the lungs is defective
mucociliary clearance, it is only logical that several therapies have been developed to
target this defect. To maintain healthy lungs, airway secretions need to be mobilized to
not only relieve airway obstruction but also reduce infection and airway inflammation.
Effective airway clearance techniques are essential components of CF therapy, hence
mucus thinners such as dornase alfa and hypertonic saline are incorporated in the therapy.
Aerosolized mucolytic agents have been incorporated into CF care to clear airway
secretions. Dornase alfa cleaves the DNA released in high concentrations by degraded
neutrophils present in CF mucus, thus reducing sputum viscosity and leading to slower
lung function decline and fewer pulmonary exacerbations. Inhaled hypertonic saline leads
to a temporary increase in mucociliary clearance by increasing the depth of the periciliary
fluid space and lowering mucus osmolality. This has been widely adopted in children and
adults with CF.18,21
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 Enzyme therapies
Just as the lungs produce thick, sticky mucus, the pancreas also makes thick mucus
that blocks the release of enzymes needed for digestion. Most people with
CF need to take enzymes before they eat. Enzymes such as creon, pancreaze, etc. work
by helping a patient digest carbohydrates, proteins and fats, gain and maintain a healthy
weight along with absorbing essential nutrients such as vitamins and minerals. 22

 CFTR Modulators
Historically, treatment of CF has focused on the downstream effects of CFTR
dysfunction, which includes impaired mucociliary clearance, chronic infection, and
chronic inflammation. The ideal therapy for CF lung disease would be to directly treat the
disease proximate to the gene or protein defect, allowing for normal or near-normal
CFTR function. Despite its early promise, gene therapy has yet to be successful in
patients with CF. One of the most exciting advances in CF therapeutics is the discovery
of small molecules that alter mutant CFTR function called the CFTR modulator
therapies. These are designed to correct the malfunctioning protein made by the CFTR
gene. They act by improving production, intracellular processing, and/or function of the
defective CFTR protein. Because different mutations cause different defects in the
protein, the medications that have been developed so far are effective only in individuals
with specific mutations. There are three approved CFTR modulators: ivacaftor
(Kalydeco®), lumacaftor/ivacaftor (Orkambi®), and tezacaftor/ivacaftor
(Symdeko®).18,23
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DISEASE EPIDEMIOLOGY

Incidence and Prevalence of CF
In 2017, around 30,000 individuals in the US and more than 70,000 worldwide were
reported to have CF (Refer Figure 5). Additionally, 1,000 new cases are diagnosed each
year and more than 75% of individuals with CF are diagnosed by the age of 2. CF is one
of the most common genetic diseases in Caucasians, occurring in 1 in 2,500 to 3,500
newborns. It is less common in other ethnic groups, affecting about 1 in 17,000 African
Americans and 1 in 31,000 Asian Americans. Worldwide, the incidence of CF is as high
as 1:377 in parts of England and as low as 1:90,000 among Asians in Hawaii. In Europe,
the rate of CF is between 1:2000 and 1:3000 births. In Southern Africa, the carrier
frequency is 1:42, with a calculated incidence of 1 in 7,056 births. The incidence in Latin
America ranges from 1:3900 to 1:8500. Estimates for the Middle East region are between
1:2560 and 1:15,876 whereas CF is rare among Asians. In India, the prevalence is
estimated at around 1:40,000 to 1:100,000 births. In Japan, the estimated incidence is
1:100,000 to 1:350,000. 24,25
Outcomes and survival rates for CF have improved drastically over the past 50 years.
Once an exclusively pediatric illness due to early mortality, individuals with CF are now
surviving commonly into adult life. The median age of patients with CF in the US is 19.3
years but some patients are as old as 87 years. Worldwide, the median survival rate varies
from country to country; and is still the highest in the US. An individual born in the US
today is expected to survive beyond 40 years of age. With current treatment strategies,
80% of the patients most likely reach adulthood. Nevertheless, CF remains a life-limiting
disease and a cure for the disease remains elusive.

15

Figure 5: Prevalence of CF from 1987-2017

Source: CF Foundation Registry Report, 2017 24
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ECONOMIC IMPACT OF CF MEDICATIONS
The mean expenditures for CF (after adjusting for inflation) doubled from
$67,000 per patient in 2010-11 to $131,000 in 2016. 26 A major contributor to this
increase was the growth in pharmaceutical spending whose share in the total spending
increased from 35.8% in 2010 to 64.1% in 2016. The growth in pharmaceutical spending
can be attributed to the introduction of specialty drugs, including the CFTR modulator
therapies. The annual wholesale acquisition costs (WAC) reported for Kalydeco®
(ivacaftor) introduced in 2012, Orkambi® (ivacaftor/lumacaftor) in 2015 and Symdeko®
in 2018 (ivacaftor/tezacaftor) are $272,886, $311,719 and $292,258, respectively. It was
observed that in patients who took ivacaftor and ivacaftor/lumacaftor, the drugs
accounted for 85% and 74% of their total pharmaceutical spending, respectively. 26,27
A 2018 report by the Institute for Clinical and Economic Review aimed to
evaluate the long-term cost effectiveness of CFTR modulator therapies. The report
concluded that all drugs (plus best supportive care) were very effective compared to best
supportive care alone in all populations studied, with the quality-adjusted life years
(QALYs) gains ranging from 5.47 to 6.73. Also, the CFTR drug-related costs ranged
from $4.9 million to $7.4 million with the incremental cost-effectiveness ratios of drugs
plus best supportive care compared to best supportive care alone being approximately
$0.9 million per QALY for all drugs in all population. Hence, at the current cost, the
CFTR modulator therapies are way over the acceptable cost-effective threshold of
$50,000-$100,000/QALY . 27
Along with CFTR modulator therapies, other specialty drugs (both pulmonary and
pancreatic therapies) have shown an annual growth of 17.1-17.3% and 9.1-9.2%,
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respectively. The increasing costs of CF medication are a huge concern to the patients
and their caregivers. Even though most patients have health insurance coverage, the
uncertainty about future insurance coverage for these expensive treatments is a constant
cause of worry.

MEDICATION ADHERENCE
Medication adherence is defined as “the degree to which the person’s behavior
corresponds with the agreed recommendations from a health care provider." 28 It usually
refers to whether patients take their medications as prescribed (e.g., twice daily), as well
as whether they continue to take a prescribed medication. Medication nonadherence
could be either intentional due to side effects, financial reasons etc. or non-intentional
like forgetting to take the medication. Medication nonadherence is a growing concern to
clinicians and other healthcare stakeholders because of mounting evidence that
nonadherence is associated with adverse clinical outcomes leading to higher healthcare
utilization.
Medication adherence can be assessed using direct and indirect methods. 29 Direct
methods include measuring the level of medicine or metabolite in the blood or any other
biological marker. Indirect methods include patient self-report, pill counts and pharmacy
refills. Although the direct methods are robust than indirect methods, they are not
practical for routine clinical use. As electronic pharmacy data are becoming available,
they are being frequently utilized for calculating medication adherence. The act of
obtaining refills and the frequency at which they are acquired depict different aspects of a
person’s adherence behavior.29 Currently, the two measures of adherence based on the
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pharmacy data reported in the literature include medication possession ratio (MPR) and
proportion of days covered (PDC). The formula to calculate these measures is as follows:


MPR= (Sum of days’ supply for all fills in the period/ Number of days in period)



PDC= (Number of days in period “covered”/Number of days in period)
The major difference between the two measurements is that the maximum value

of PDC is 1.0 which indicates full adherence whereas MPR takes oversupplies into
consideration and can have a value of greater than 1.0.
Patients with CF and their caregivers face constant challenge of fitting complex
treatment routines into their daily schedule. It has been estimated that these routines
consume nearly 2 hours every day out of their schedule that is already covered with
school family, work and other commitments. Adherence to CF care plans is critical as
nonadherence is linked to poor health outcomes resulting in longer hospital stays, higher
respiratory exacerbation cost, increased hospitalizations, increased number of pulmonary
exacerbations requiring intravenous antibiotics, and lower baseline lung function.30,31
A study assessing the association of adherence to pulmonary medications to lung
health outcomes in CF population reported that group with the lowest adherence (<50%)
had the highest probability of having an exacerbation.32 Another study reported an
association of lower adherence to dornase alpha to longer lengths of hospital stay and
higher costs of pulmonary exacerbations.33 Research indicates that lower adherence to
medications maybe in part due to difficulties with time management, forgetfulness,
increased regimen complexity, decreased parental supervision in adolescents, perceived
doubts about the necessity of treatments, stigma and reluctance to disclose CF status, and
depression in both patients and their caregivers.34
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Also, most patients with CF reported that added time burden in working with their
insurance payers and pharmacies to obtain the appropriate prior authorizations and
approvals for the specialized medications as a barrier to care. Cost containment efforts by
payers including restricting these medications in their formulary presents additional
burden for patients and providers. There is a need to develop policies to streamline this
process so as to help individuals obtain their medications on a routine basis and assist
with being adherent to their medications.31

PROBLEM STATEMENT
CF is a complex disease that requires a patient to take a number of medications on
a daily basis to avoid disease-related complications. Even with the consumption of
numerous medications, generally the disease symptoms are controlled. However, with the
introduction of CFTR modulator therapies, patients (with specific mutations) have an
opportunity to slow the disease progression. As these expensive medications are orally
administered, there is a need to assess their adherence. Currently, there is a dearth of
studies reporting the adherence rates of CFTR modulator therapies. Given their high
acquisition cost, assessing their adherence rate is warranted.
In recent times, a lot of focus has been placed on the increasing costs for the CF
treatments. Few studies have assessed the overall medication costs in CF population but
only one study was conducted after the introduction of CFTR modulator therapies. Also,
this study did not assess the cost of medications specifically prescribed for comorbidities. Given the high burden of comorbidities in CF population, the cost of
medications for other co-morbidities can be substantial. Thus, there is a need to evaluate
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the economic burden of medications for co-morbidities along with CFTR modulator
therapies.

CONCEPTUAL FRAMEWORK
This study will utilize real-world data from AllianceRx Walgreens Prime
Specialty Pharmacy, which provides CF management program, reimbursement support
and patient advocacy to its patients. Pharmacy dispensing records and self- reported
patient assessment data will be analyzed to provide an overview of the utilization pattern
of CFTR modulator therapies. This study will involve all the patients who had a
minimum of one dispensing record of a CFTR modulator therapy at AllianceRx
Walgreens Prime Specialty Pharmacy from January 2015 to August 2018.

Part I
In the AllianceRx Walgreens Prime Specialty Pharmacy database, every patient is
assigned a unique Patient ID. This Patient ID is linked to their CFTR dispensing
information, which was utilized to calculate PDC, as an adherence measurement.
Furthermore, AllianceRx Walgreens Prime Specialty Pharmacy routinely collects patient
data regarding switching, forgetting and discontinuing of therapies. This self-reported
data was analyzed to describe the problems associated with CFTR modulator therapies.

Part II
As the CFTR modulator therapies are extremely expensive, there can be a
substantial cost to the patient as a part of the copay even though the medications may be
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covered by the health insurance plans. Therefore, the study will calculate the average copay associated with each CFTR modulator therapy depending on the insurance status of
the patient. AllianceRx Walgreens Prime Specialty Pharmacy also collects information
regarding the comedications of patients, which will be used to understand the economic
burden of these medications in CF.

STUDY HYPOTHESIS
The hypothesis for the first part of the study is that the adherence rate of patients
to CFTR modulator therapies will be high given the nature of the disease. The hypothesis
for the second part is that there is a substantial economic burden associated with co-pay
on the patient with CF for CFTR medications and cost of comedications.

STUDY SIGNIFICANCE
The adherence to CFTR modulator therapies is important in order to slow the
disease progression and avoid further complications. Since adherence has not been
reported in the literature, this study will the first to assess the adherence rates of these
medications in CF. Using the specialty pharmacy data for CFTR modulator therapies, the
study will also provide useful data on the real-world trends in CF.
While adherence rate calculations are important, analyzing the reported reasons
for missing doses or discontinuing therapies is also important as it will help us understand
the motives behind lower adherence rates. This can potentially assist providers in creating
interventions that can improve adherence, which in the long run can reduce the healthcare
spending. Similarly, assessing the relationship between adherence and payer
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characteristics (if any) will highlight the importance of secondary payer. This information
can be utilized by specialty pharmacies in guiding their patients to choose the right
payment plan for their treatment.
With the emphasis on the cost of CFTR modulator therapies, only a handful of
studies have assessed the cost of other medications in the treatment of CF. Along with the
symptoms of CF, patients suffer from additional co-morbidities resulting in substantial
treatment costs. Hence, this study will be among the few to assess the economic burden
of comedications in CF. This will include the cost of medications related to symptom
management of CF as well as unrelated to CF. This information will help all the
stakeholders involved in CF care to understand the medication spending patterns. This
has implications for future resource allocation decisions.

STUDY OBJECTIVES AND RESEARCH QUESTIONS
The study objectives and specific research questions are as follows:

Part I: Utilization of CFTR modulator therapies
To assess the utilization of CFTR modulator therapies in a specialty pharmacy CF patient
population
Research Questions:
1.

To describe the demographics, medication utilization, and insurance characteristics
for patients on CFTR modulator therapies

2.

To identify reasons for missed doses, medication discontinuation, and CFTR
modulator therapy-related adverse events

3.

To calculate medication adherence rate using PDC as a measure for patients with
more than one refill for CFTR modulator therapies and explore the association
23

between medication adherence rate and payer characteristics (those with and without
secondary insurance)

Part II: Economic burden of CFTR modulator therapies and co-medications
To calculate the economic burden of CFTR modulator therapies and medications utilized
for other comorbidities in the CF population.
Research Questions:
1. To analyze the spending pattern of the specialty pharmacy on CFTR modulator
therapies from 2015-2018
2. To identify the average co-pay of patients for CFTR modulator therapies based on
payer type
3. To estimate the burden of medications (Other CF & non-CF medications) in the CF
population
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CHAPTER 2: SYSTEMATIC LITERATURE
REVIEW
The economic burden related to CF treatment has increased considerably over the
last decade, especially with the introduction of CFTR modulator therapies. Thus, the total
treatment costs of CF in the US and globally needs to be examined. This chapter reports
the findings of a systematic literature review conducted to estimate the economic burden
of CF.

METHODS
Following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guideline, a systematic literature review was conducted to identify
published literature from January 2008 till December 2018. The search strategy was
developed using keywords related to CF and economic burden (Refer Table 2). The
search strategy was then executed in PubMed and Scopus databases (Refer Appendix I).
Articles identified in the search were screened for duplicates following which their title
and abstracts were reviewed against inclusion/exclusion criteria and relevancy to study
objectives. Further, the articles underwent full text review and those that met the study
objectives were included in the final review.

Inclusion/Exclusion Criteria
English-language articles which quantified the burden of CF using real world cost
data in monetary units were included in this review. Articles which estimated the burden
of diseases using economic models were excluded from the study along with review
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Table 2: Keywords used in the search strategy
Keywords related to

Keywords related to economic burden

CF
Cystic Fibrosis,
Mucoviscidosis

Economics, cost of illness, cost of disease, cost of sickness,
healthcare costs, healthcare expenditure, healthcare
utilization, direct service costs, hospital cost,
hospitalization cost, drug cost, economic burden, economic
impact, economic cost, economic analyses, economic
consequence, economic implication, medical expenditure
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articles, theses/dissertations, conference abstracts, commentaries, editorials, and
systematic reviews.

RESULTS
The search strategy identified a total of 1,285 articles from PubMed and Scopus.
After removing 261 duplicates, 1,024 articles were screened against the
inclusion/exclusion criteria and 30 were included in this review (Refer Figure 6). The
studies were conducted in 13 countries covering three regions including Europe (n=16,
53%), North America (n=12, 40%) and Australia (n=2, 7%). The methodology of the
studies varied from primary data collection in patients and/or physicians to secondary
data analyses. All the studies estimated the direct medical costs of CF while a few (n=6,
20%) quantified the CF-related indirect costs.
In international studies, the major direct medical costs included hospitalization
costs, physician visits, medication use and pathology tests. A number of studies (n=6,
37.5%) concluded that as a single cost item, medications were the major cost drivers of
CF-related direct costs. Mlcoch et al. estimated that out of the total direct medical costs
of €14,486 (2018- $18,474.26) per patient in the Czech Republic, €10,321(2018$13,162.55) was spent on medications.35 Huot et al. estimated that medications accounted
for 45% of the total CF-related direct medical costs per patient in France while
Heimeshoff et al. estimated that 76% of total (direct and indirect) costs were due to high
drugs costs per patient in Germany. 36,37 Angelis et al. reported that the direct nonmedical costs were the largest component (44.3%) of the total average costs per patient in
the United Kingdom (UK). 38 Within the direct non-medical cost category, informal care
had the biggest share averaging €21,447 (2018- $28,362.88), accounting for 99.6% of the
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Figure 6: Schematic representation of the systematic literature review

Reference: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The
PRISMA Statement 39
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direct non-medical costs and 44.1% of total costs. Informal care was operationalized as
the time spent by non-professional caregivers helping the patient with their basic
activities of daily living. 38
While international studies estimated all the cost components of CF, the US-based
studies assessed only the direct medical costs related to the disease. Hospitalizations,
outpatient visits and pharmacy costs were the most frequent resources captured in the US
studies. Briesacher et al. observed that the per person costs for CF increased by 61%
from 2001 to 2007 while the prescription drug costs increased by 66% during the same
time period. 40 Similarly, Grosse et al. reported that the expenditure in commercially
insured individuals with CF doubled from 2010 to 2016 but the total spending on
pharmaceuticals increased from 35.8% to 64.1% in 2016. 26
Although all of these studies have utilized various resources to calculate the
economic burden associated with CF, only two of them have included the cost of CFTR
modulator therapies. Corcoran et al. calculated the drug acquisition cost for ivacaftor at
€29.81 million (2018- $37.01 million) for a total of 140 people in Ireland. 41 Similarly,
Grosse et al. observed that in 5.8% of CF patients who took ivacaftor in 2016 in the US,
the drug accounted for 85% of their pharmaceutical spending and lumacaftor/ivacaftor
taken by 17.6% of the CF population accounted for 74% of their total pharmaceutical
spending.26 Overall, there seems to be an increase in the cost of CF treatment which
could be attributed to the introduction and increase in the utilization of CFTR modulator
therapies along with the inflation over the years.
The studies included in this literature review are summarized in Tables 3 and 4
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Table 3: Description of International studies
Author,
Year,
Country
Corcoran et
al, 41
2017
Ireland
Jackson et
al, 42
2017

Objective

Type of data

Type of resources

Year,
Currency

Key Findings

To analyze the High-Tech Drug
Scheme pharmacy claims database
over a 12-month period (from
January 2015 to December 2015
inclusive) to examine the number of
individuals who had been prescribed
Ivacaftor and the expenditure.
To examine the direct medical cost
borne by the health service in
providing healthcare resources and
services for CF in Ireland in 2008–
2012.

The HighTech Drug
Scheme
pharmacy
claims

Drug acquisition
expenditure

2015,
Euro



The cumulative drug acquisition
expenditure on Ivacaftor over the
12-month study period was
€29.81 million for a total of 140
individuals

The CF
Registry of
Ireland and the
state-funded
public
healthcare
scheme
Hospital
Inpatient
Enquiry
system

Medication costs,
Day care cost,
Inpatient cost

2014,
Euro



To understand the regimen of
pharmacotherapy in adult CF
population in Poland, and to
calculate the costs of drugs used in
this group of patients.

Data from a
CF hospital
clinic

Medication costs

To calculate costs associated with CF
treatment in Poland as well as at
comparison of average costs of
treatment of CF patients in selected
countries, taking into account the
purchasing power parity.

Data from a
CF hospital
clinic

The median annual total cost per
patient increased over the period
2008–2012 from €12,659 to
€16,852
Inpatient bed-day cost increased
from €14,026 to €17,332
Medication cost increased from
€5,863 to €12,467
Homozygous F508-CFTR
mutation (class II) cost was
highest and milder mutation
(class IV/V) cost was 49% lower.
Total pharmacotherapy cost in
2013 amounted to €467,876.66
giving €10,171.23 (± 2818.39)
per patient.
The most popular group of drugs
used by CF patients was
mucolytic drugs, with the
estimated cost of €382,054.21.
Total annual treatment cost per
one CF patient in Poland was on
average €19,581.08.
Total direct costs amounted to
€634,714.37 (on average:
€13,798.14 per year).

Ireland
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Kopciuch et
al, 43
2017





2013,
Euro



Poland

Kopciuch et
al, 44
2017
Poland



Direct Costs:
hospitalization,
outpatient visits,
pharmacotherapy,
diagnostic tests and
transportation
Indirect Costs:

2013,
Euro




Presenteeism

Mlcoch et
al, 35
2017

To retrospectively assess CF health
care costs within a representative
cohort of Czech patients drawn from
the Prague CF Center.

Data from
Prague CF
Center

Czech
Republic

Chevreul et
al, 45
2016
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Bulgaria,
France,
Germany,
Hungary,
Italy, Spain,
Sweden and
UK

Angelis et
al, 38
2015

To estimate the social/ economic
costs considering three dimensions—
direct healthcare costs, direct nonhealthcare costs (formal and informal
care), and labor productivity losses—
and to assess Health related quality
of life (HRQoL) in patients with CF
and their caregivers in Europe.

To estimate the societal costs of CF
by accounting for all direct health,
direct non-health care and indirect

Collected from
patients
identified
through CF
reference
centers, patient
associations or
national
registries

Collected from
a questionnaire
using
convenience

Inpatient Care
(hospitalization
costs)
Medicinal Products
and Devices (drug
costs) Procedures
(laboratory
examinations,
diagnostics, and
outpatient care)
Direct healthcare
costs- drugs,
medical tests,
medical visits,
hospitalizations,
medical devices and
healthcare transport
Direct nonhealthcare costsprofessional care
(provided either at
home by a
professional
caregiver or in
institutions run by
social services) and
non-healthcare
transport
Indirect costs- Labor
Productivity losses

2010,
Euro

Direct Health Care
Costs: Prescription
medication, Tests,
Outpatient &

2012,
Euro



Direct costs made up the largest
share of total costs, and direct
medical costs made up as much
as 70% of total costs.



The mean total health care costs
were €14,486 per patient, with
the majority of the costs going
towards medicinal products and
devices (€10,321).
Medical procedures (€2676) and
inpatient care (€1829)
represented a much smaller
percentage of costs.



2012,
Euro












The total mean cost of CF varied
from €21,144 in Bulgaria to
€53,256 in Germany.
Healthcare costs ranged from
€12,161 (Bulgaria) to €28,827
(Germany).
The main items were
hospitalizations and drugs.
Non-healthcare costs ranged
from €6,313 (Hungary) to
€21,528 (UK), with informal
care being the highest cost item.
Labor productivity losses ranged
from €1,094 (Bulgaria) to
€12,443 (UK).
Adults had higher direct
healthcare costs than children,
but children had much higher
informal care costs.
Total costs increased with
patients’ level of dependence.
Estimated average annual cost
per patient in 2012 was €48,603,
and the median was €34,883.

UK
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Chevreul et
al, 46
2015
France

costs, and, second, to assess the
HRQoL of patients with CF.

To provide data on the economic
burden and HRQoL associated with
CF in France.

sampling from
CF trust

Collected from
patients
recruited
through the CF
reference
centers

primary health care
visits, Acute
hospitalization,
Medical devices,
Health care
transportation
Direct Non-Health
Care Costs: Nonhealth care
transportation,
Social services,
Caregiver time costs
(informal care),
Main caregivers,
Secondary
caregivers
Loss of Labor
Productivity: Sick
leave, Early
retirement
Direct Healthcare
costs- Drugs,
Medical tests,
Consultations,
Hospitalizations,
Medical devices,
Healthcare transport
Direct non-HC costs
(formal)Professional carer,
social services, NonHC transport
Direct non-HC costs
(informal)-Main
informal carer,
Other informal
carers
Indirect costsProductivity loss





2012,
Euro








Direct non-health care cost was
the largest component (44.3 % of
the total average cost per
patient), followed by direct
health care costs (42.9 %) and
productivity loss (12.8 %).
On average, the largest
expenditures by far were
accounted for by informal care
(44.1 %), followed by
medications (14.5 %), acute
hospitalizations (13.9 %), early
retirement (9.1 %) and outpatient
and primary health care visits
(7.9 %).

The total average annual cost of
CF was €29,746 per patient.
Direct healthcare costs accounted
for over half, with drugs and
hospitalizations representing the
largest shares.
Direct non-healthcare formal
costs were estimated at €4,512,
with social services accounting
for 92.6% of that cost.
Direct non-healthcare informal
costs were similarly high
(€4,827).

(patients), Early
retirement (patients)

Gu et al, 47
2015

To identify potential predictors of
resource use in the management of
CF, and examine how these
predictors affect health care costs

Australian CF
Data Registry

To estimate the social economic
costs in a triple dimension of direct
health care costs, direct non-health
care costs (formal and informal care)
and labor productivity losses, as well
as to assess the health-related quality
of life (HRQoL) of Bulgarian CF
patients and their caregivers

Questionnaire
administered
to patients
from CF
patient’s
organization

To estimate the mean annual costs
associated with the treatment of CF
patients for the Italian National
Healthcare Service

Collected
through a
sample of CF
patients

Australia

Iskrov et al,
48

2015
Bulgaria
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Colombo et
al, 49
2013
Italy

Hospitalizations,
clinical visits,
medication use,
nutritional
supplements,
oxygen therapy and
home intravenous
therapy
Direct costs: Drugs,
Tests, Visits,
Hospitalizations,
Materials, Health
care transport,
Social services,
Professional care,
Non-health care
transport, Main
informal carer,
Other informal
carers
Indirect costs:
Patient’s loss of
productivity,
Patient’s early
retirement
Direct medical
costs- drug costs,
hospitalization costs
and costs associated
with outpatient
medical
interventions

2009,
Australian
Dollar



The mean and median costs were
A$33,563 and A$23,685

2012,
Euro



Median annual costs of CF in
Bulgaria were €24,152 per
patient.
Median annual costs for children
were found to be significantly
higher than those for adults –
€31,945 vs. €15,714.
As a single cost item, drugs had
the biggest monetary impact.
Median annual drug costs were
€13,059





2009,
Euro



The mean annual cost/patient
increased with age and lung
disease severity from €4,164 in
children aged ≤5 years to
€30,123 in patients aged >5 years
with severe lung disease

Van Gool et
al, 50
2013

To estimate the rate of CF
progression for various age groups
and health states as well as the health
care costs associated with treating CF

Australian CF
Data Registry

To calculate the average total costs
of CF per patient and per year from a
societal perspective; to include all
direct medical and non-medical costs
as well as indirect costs; to identify
the main cost drivers; to investigate
whether patients with CF can be
grouped into homogenous cost
groups according to defined severity
levels; and to determine the influence
of certain factors on different cost
categories.

CF treatment
center

Australia

Heimeshof
et al, 37
2012
Germany

34
Eidt-Koch
et al, 51
2011
Germany

Detailed evaluation of direct costs in
outpatient treatment of CF patients in
Germany measured by valuing the
actual consumption of resources and
a comparison of these costs with the
current reimbursement situation
within the statutory health insurance
system

Data from
seven German
pediatric and
adult CF
outpatient
units based at
university
hospitals

Hospitalizations in a
year, prescription
medications, types
of dietary
supplements used,
number of clinical
visits, use of oxygen
therapy, and some
pathology tests
Direct medical
costs: Drug costs,
laboratory costs,
staff costs for
patient care and
overhead costs
Direct non-medical
costs: travel
expenses
Indirect costs: Costs
of absence from
work and
productivity losses
due to CF.

2009,
USD



The mean annual cost associated
with CF management is US
$15,571, with a 95% confidence
interval range of US $15,032 to
US $16,110.

2004,
Euro



Outpatient costs:
Routine medical
examinations,
Laboratory
investigations,
Diagnostic services,
Physiotherapy,
dietician, etc.,

2006,
Euro

The mean total cost per patient
per year was €41,468.
Direct medical costs (inpatient
and outpatient care including
outpatient drugs) averaged
€38,869 per patient per year and
accounted for 94% of total costs.
Indirect costs amounted to
€2,491 (6% of total costs).
Costs for drugs patients received
at the outpatient pharmacy were
the main cost driver.
Costs rose with the degree of
severity. Patients with moderate
and severe disease had
significantly higher direct costs
than the relatively milder group.
Costs due to the resources used
in the clinic add up to mean of
488 per patient per quarter in
2006.









Hollmeyer
et al, 52
2011
Germany

Eidt-Koch
et al, 53
2010

To identify per patient average
resource use and costs for personnel
at a CF outpatient center from the
health care provider’s perspective; to
assess whether outpatients can be
grouped into cost homogenous
clusters of patients according to sex,
age group, and disease severity
levels; and to evaluate the value of
demographic and clinical variables in
predicting staff costs.
To analyze in detail the costs of
outpatient medication for CF patients
in Germany from a sickness funds
perspective

Germany

Data from
hospital-based
outpatient CF
care

Staff costs

2004,
Euro



The mean total staff costs per
patient amounted to €142.3 over
six months of outpatient service,
ranging from €22.1 to €669.

Data from
seven German
pediatric and
adult CF
outpatient
units based at
university
hospitals

Medication costs

2006,
Euro



The total daily medication cost
for all 301 patients was €17,815,
resulting in mean daily
medication costs in outpatient
treatment of €59.19 per patient.
An extrapolation to 1 year of
treatment yielded total outpatient
medication costs of €6,502,791
for the 301 study patients, with
average costs of €21,603 per
patient per year

Tuscan
regional CF
center

Prescription costs



35
Braccini et
al, 54
2009
Italy

The aims of the study were to: define
the costs of antibiotic treatment of
Tuscan CF patients with P.
aeruginosa infection treated
according to the Consensus statement
6; to describe the differences in cost
of antibiotic treatment in patients
with first or new P. aeruginosa
infection compared to those with
chronic infection; and to analyze the
differences regarding the prescription

2006,
Euro





Total costs over the period 20022006 amounted to €384,207.00
with a mean cost per patient of
€6,298.00 (€1,259.00 per patient
per year) for early eradication
treatment.
85.7% of the costs of antibiotic
treatment (€2,303,852.00) were
for treatment of patients
chronically infected by P.
aeruginosa while only 14.3% of

and cost of antibiotic treatment for
outpatients and inpatients.



Huot et al, 36
2008
France

To evaluate the trends in CF related
costs following the advances in CF
management in France.

CF Reference
Center

36

Home care:
Medications,
Physician
consultations,
Physiotherapist
consultations,
Nursing care,
Medical devices,
Lab and radiological
tests, IV-antibiotic
therapy, Nebulizer
rentals
Hospital care:
CFRC visits,
Outpatient
hospitalizations,
Inpatient
hospitalizations

2003,
Euro







costs (€384,207.00) were for
treatment of inpatients who had
undergone early antibiotic
treatment. year) for early
eradication treatment.
Of the €2,303,852.00 overall cost
of antibiotic treatment for
chronically infected patients,
€2,125,733.00 (95%) were for
outpatients and €115,119.00
(5%) for inpatients.
Average cost of CF was
€16,474/patient/year in 2000,
and €22,725 in 2003.
Hospital care increased from
15% of the total cost in 2000 to
22% in 2003.
Medications accounted for 45%
of the total cost for the two
periods, with an average cost of
€7229/patient/year in 2000 and
€10,336 in 2003.
Home intravenous antibiotic
therapy accounted for 20% of the
total cost for the two periods.

Abbreviations: CF- Cystic Fibrosis; UK- United Kingdom; HRQoL- Health related quality of life, US – United States

Table 4: Description of studies conducted in the United States
Author,
Year,

Objective

Type of data

Type of resources

Year,
Currenc
y

Key Findings

Grosse et al,

To describe current
trends in health care
expenditures for
commercially insured
patients with CF in the
US.

The IBM Watson
Truven Health
MarketScan®
Commercial
Database (a
nationwide
convenience sample
of claims data)

Inpatient services
Outpatient servicesoutpatient encounters,
emergency room (with
discharge home),
laboratory tests, and
durable medical
equipment for
respiratory support
Outpatient
pharmaceuticals

2016, USD



Medical and
pharmacy claims data
from the Truven
Health MarketScan®
Medicaid Multi-State
Database.

Inpatient, Outpatient and
Pharmacy costs
described over a year as
well as during each
pulmonary exacerbation
event

2014, USD
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2018

37

Hassan et al,
55

2018

To describe the overall
burden of CF in this
population, particularly
in terms of the incidence
of Pulmonary
exacerbations (PEx)
episodes and their
associated costs as well
as Inpatient admissions,
antibiotic use, and
overall health care
resource utilization.










Median expenditures increased
from $32,586 in 2010 to $67,760
in 2016, more than doubling in a
period of 5 years.
The share of pharmaceuticals in
total spending increased from
35.8% in 2010 to 64.1% in 2016.
The annual growth rate in
pharmaceutical spending rose by
33.1% during 2014-2016, the
years during which
lumacaftor/ivacaftor was
introduced.
Mean (SD) health care costs
during a PEx event were
US$75,623 (US$205,236),
driven by Inpatient costs of
US$58,468 (US$197,046), and
followed by Outpatient costs
(US$2882 [US$7430]), office
visits (US$233 [US$314]), and
ER visits (US$169 [US$670])
Mean (SD) pharmacy costs were
US$14,273 (US$21,415) and
mean (SD) antibiotic costs were
US$5716 (US$10,555).
Among mean (SD) antibiotic
costs, inhaled was highest at
US$3934 (US$7961), followed
by oral at US$1270 (US$4293),
and lastly IV at US$320
(US$1757)

Vadagam et
al, 56
2018

Agrawal et
al, 57
2017

2012, USD



To determine patient,
hospital, and clinical
characteristics associated
with the length of stay,
total hospital charges,
and total hospital costs in
CF.

Kid’s Inpatient
database and
National Inpatient
Sample data collected
by Healthcare Cost
and Utilization
Project (HCUP)

Hospital charges and
hospital costs

To assess recent changes
in the frequency and cost
of inpatient admissions
for a principal diagnosis
of CF patients in the US
from 2003 to 2013

National Inpatient
Sample from HCUP

Hospital Charges

2003 to
2013, USD



To examine the burden
of PEx and associated
costs among a national
sample of pediatric and
adult patients with CF
with commercial
coverage from a large
US health insurer
affiliated with Optum
from 2008 to 2013

Administrative
claims data from a
large, US health
insurer with national
coverage

Cost associated with
pulmonary exacerbation
event

2013, USD



To estimate the cost of
care for a unique cohort
of children with CF
followed over time from

Data from Wisconsin
newborn screening
study

Inpatient costs,
Outpatient costs and
drug costs




Among children, the mean
hospital costs were $26,249.23
(40,592.81).
Adults had mean hospital costs
of $21,600.91 (31,997.52)
Total hospital charges were
higher in patients covered under
Medicare and hospitals with a
small bed size while total
hospital costs were higher in
people without any insurance
and hospitals with a medium bed
size.
The aggregate cost of hospital
visits of patients with the
principal diagnosis of CF
increased 138.31% from US
$500,105,727 in 2003 to US
$1,191,819,760 in 2013.

38
Rubin et al,
58

2017

Levy et al,
59

2016



2010, USD



The mean cost per episode was
$12,784 for PEx of any type and
$36,319 for inpatient stay
Mean (median) annual costs
attributable to PEx of any type
were $37,025 ($10,833) among
all patients and rose with stage
of lung disease from $30,066
($9456) among patients with
mild disease to $119,862
($48,263) among patients with
severe disease
Seventy-three children were
followed for an average of 12.9
years with an average annual
total cost of care of $24,768.



infancy, and separately
identify cost of care by
different disease risk
factors known at birth.

Snell et al,
60

2014


Reviewing hospital
charts

Hospital admissions,
outpatient clinic visits

USD



To describe the
P.aeruginosa infectionassociated healthcare
utilization and costs
across the spectrum of
care among CF patients
in the US managed care
population.

MarketScan
Commercial Claims
and Encounters
database for 2005–
2008

Inpatient care: visits,
hospital length of stay
Outpatient care:
physician visits, urgent
care visits,
emergency room visits
Prescriptions: total
number of prescription
claims,
total number of unique
claims

USD
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To examine the potential
relationships between
depression, overall
treatment adherence,
medical outcomes, and
healthcare utilization
with the goals of
identifying the impact of
mental health issues on
health outcomes and
healthcare costs in CF

Outpatient drug costs (53%) and
hospitalizations (32%)
represented the majority of costs.
The average annual drug costs
were $13,068 with $6,292 (48%)
representing pulmonary drugs.
Hospital-based charges for the
depressed group were on average
more than four times higher than
those for the non-depressed
group (means of $280,000 and
$60,116, respectively)

Sansgiry et
61
al,
2012





Pre-infection annual per-patient
medical expenditures were
$33,305.
After infection, annual perpatient expenditures increased to
$51,821, a jump of more than
$18,500 relative to baseline
value.
Inpatient care was the single
largest contributing factor, with
an increase of $8580 over
baseline expenditures.

Kopp et al,
62

2012

Briesacher
et al, 40
2011

To compare costs and
discharge rates among
adult CF patient
hospitalizations in terms
of location of
hospitalization.
To provide the first
comprehensive
evaluation of changes in
CF healthcare costs over
time and report overall
annual trends in outpatient visits, inpatient
admissions, and
prescription drug use
between 2001 and 2007
for a national sample of
individuals with CF.

National Inpatient
Sample from HCUP

Hospital Charges

2007, USD



Adjusted mean hospital charges
had no difference for patients in
pediatric ($53,095) and adult
($59,627) hospitals

Healthcare claims
from Medstat
MarketScan
Commercial Claims
and Encounters and
Medicare
Supplemental
Databases (Ann
Arbor, MI)

Total costs, included
inpatient costs,
outpatient costs, and
prescription drug use.

2007, USD



Overall, the yearly costs per
person of prescription drugs,
outpatient visits, and durable
medical equipment increased by
61% during the 7-year period
($18,715 in 2001 vs. $29,718 in
2007).
Outpatient medical care costs
increased, on average, 57% from
$7,648 in 2001 to $12,040 in
2007
Prescription drugs increased
66% ($10,121 in 2001 to
$16,804 in 2007).
Largest increases in total
medical care costs occurred for
the oldest CF patients
Mean annual costs for CF
totaling about $29,000 per
patient plus another $20,000 for
prescription drugs.
Inpatient hospital costs were
$22,102 for CF-related stays and
$26,761 for stays for any
diagnosis.
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O’Sullivan
et al, 63
2011

To examine health care
utilization and costs over
one year among CF
patients with pulmonary
infections.

Medical and
pharmacy claims data
for commercial and
Medicaid enrollees
from a large US
health plan

Physician office visits,
out- patient hospital
visits, ER visits, inpatient stays, and
prescription drugs.

2006, USD





Ouyang et
al, 64
2009

To characterize annual
medical expenditures
incurred by people with a
medical diagnosis of CF
among a privately
insured US population.

MarketScan
Commercial Claims
and Encounters
database

Person-specific clinical
utilization, expenditures,
and enrollment across
inpatient, outpatient, and
prescription drug
services.

2006, USD









Total medical care expenditures
averaged $48,098 for people
with CF, more than 22 times the
average of $2,172 for people
without CF.
People with CF had mean annual
expenditures for inpatient care
that were 35 times higher
($16,545 vs. $467) than those for
people without CF.
Expenditures for prescribed
medications were 42 times
higher ($18,461 vs. $437) among
those in the CF group.
Average expenditures for
outpatient visits were 10 times
higher ($13,092 vs. $1,267) for
those with CF than for those
without CF.
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Abbreviations: US- United States; CF- Cystic Fibrosis; PEx- Pulmonary Exacerbation; HCUP- Healthcare Cost and Utilization
Project

LIMITATIONS
This study has a few limitations that should be considered. The heterogeneity of
the literature (among populations, treatments, measurements, and outcomes) identified in
this review made individualized quality assessments of the studies using a particular
method extremely difficult. Though we tried to incorporate both international and US
studies in our review, international non-English studies containing relevant information
might have been excluded. Also, readers need to account for any differences in the
healthcare systems before interpreting the results of US and international studies.

CONCLUSIONS
This systematic review provides a comprehensive summary of the studies that
have estimated the burden of CF over the last decade. Among these, very few studies
have included the cost of CFTR modulator therapies and even the few that have, only
focused on one CFTR modulator therapy (ivacaftor). With three high acquisition cost
CFTR modulator therapies currently in the market, there is a need to provide a more
current estimate of the economic burden associated with CF, especially focusing on
CFTR modulator therapies.
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CHAPTER 3: METHODS
The overall goal of the study was to assess the utilization of CFTR modulator
therapies in patients with CF. Utilization data on CFTR modulator therapies was sourced
from AllianceRx Walgreens Prime specialty pharmacy, one of the nation’s largest
specialty pharmacy providers. The study was approved by the Institutional Review Board
(IRB) of Duquesne University and the legal team of AllianceRx Walgreens Prime
specialty pharmacy.
This chapter includes a detailed description of the specialty pharmacy database,
study variables and the analytical techniques employed in the study.

ALLIANCERX WALGREENS PRIME SPECIALTY PHARMACY
DATABASE
AllianceRx Walgreens Prime specialty pharmacy offers various services from
refilling and shipping of specialty medications to counseling patients regarding
medication adherence and adverse events associated with medications. As per their
protocol, data is captured in an electronic format using pre-defined variables at each step
of the process. For this study, de-identified data from patients with CF using CFTR
modulator therapies (Kalydeco, Orkambi and Symdeko) was provided by AllianceRx
Walgreens Prime specialty pharmacy to the researchers.
Depending on the point of data collection, the data can be broadly categorized
into two parts: refill data of CFTR modulator therapy and routine patient assessment data.
During the collection of the refill data, patient’s demographics, medication information
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and insurance details are collected. For this study, refill data from 1 st January 2015 to 31 st
August 2018 was provided by the AllianceRx Walgreens Prime specialty pharmacy. For
the specific study variables included in the refill data refer Table 5.
The second data included in the study was the routine patient assessment data,
which is collected during the induction of the patient in the pharmacy, generally when
filling the first prescription. A patient care coordinator (PCC) and a pharmacist complete
the initial patient assessment. Additionally, before each refill, a PCC administers a refill
assessment survey that provides information on medication switching, discontinuation,
missed doses and any side-effects that the patient may be experiencing. If the patient has
specific concerns, the case gets escalated to a pharmacist who then completes the
assessment and counsels the patient on the specific problem. At each stage of the process,
the patient responses are documented in the electronic dataset. For this study, patient
assessment data from 30 th April 2014 to 30th August 2018 was provided by AllianceRx
Walgreens Prime specialty pharmacy. Table 6 lists the study variables from the patient
assessment dataset were utilized in the analyses.

DATA EXTRACTION
The researchers worked alongside a team of AllianceRx Walgreens specialty
pharmacy employees to identify variables needed for these analyses. The data extraction
for these variables was then conducted by AllianceRx Walgreens specialty pharmacy and
de-identified files were provided to researchers at Duquesne University. These deidentified datasets consisted of the exact constraints needed for the study hence no further
cleaning of the data was necessary. In the refill data file extracted from the specialty
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Table 5: Variables included in the refill data
Variables included in the refill data
Patient ID

Drug Name

Secondary Payer Name

Patient Age

Quantity

Secondary Payer Type

Patient Sex

Day Supply

Secondary Copay

Patient State

WAC

ICD Codes

Refill Number

Price

Allergy

Fill Date

Primary Payer Name

Other Medications

Ship Date

Primary Copay

Table 6: Variables present in the patient assessment dataset
Variables present in the patient assessment dataset
Patient ID

Side Effects Reason Question ID

Assessment Date

Side Effects Reason Question

Drug Name

Side Effects Reason Response

Discontinued Medication Question ID

Missed Doses Reason Question ID

Discontinued Medication Question

Missed Doses Reason Question

Discontinued Medication Response

Missed Doses Reason Response

For variable description refer Table 7
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pharmacy dispensing system, each row represented a new fill or a refill for a patient.
Similarly, in the patient assessment data extracted from the specialty pharmacy clinical
system, each row represented a response of the patient to a particular question asked by a
PCC or a pharmacist during each patient encounter. Thus, in both files, a single patient
can have multiple rows of data. After the Excel files were received by researchers at
Duquesne University, they were converted into Statistical Analysis System (SAS) files
(SAS Institute University Edition; Cary, NC) dataset. Further analyses were performed
using both excel and SAS files. All the SAS codes used for data extraction and analyses
are attached in Appendix II.

STUDY VARIABLES
The variables from refill and patient assessment data used in this study are described in
Table 7.

DATA ANALYSIS
In this section, the analytical techniques for each study objective are described.

Objective 1
To describe the demographics, medication utilization, and insurance characteristics for
patients on CFTR modulator therapies.
Descriptive analyses (mean, standard deviation, median, and frequency
distribution) were conducted to provide a distribution of patient (age, sex, and residence)
and clinical factors (co-morbidities and allergies). Further, all medication utilization and
insurance characteristics were described using the data collected on the last refill (most
recent) of the patient in the database.
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Table 7: Variable Descriptions
Variable Name

Description

Patient ID

A unique identifier was assigned to each patient in the
AllianceRx Walgreens Prime specialty pharmacy database.
The patient’s date of birth was utilized to calculate the age as on
30th January 2019. For further analyses, two age categories were
created: ‘below 18 years’ and ‘equal to or greater than 18 years.’
Sex was categorized as male or female.
The state in which the patient resides was used to create four
regions of the US: Northeast, Midwest, South and West.
Patient’s self-reported allergies were captured in the refill data
set and were presented as none, one or more than one allergy.
Patient reported all the medical conditions they suffered from
including CF. These were reported in the database in the form of
ICD-9 and ICD-10 codes. Patients could have none, one, or
more than one co-morbidity. The co-morbidities are categorized
as shown in the Table 8.
The insurance details for each refill filled by the patient included
the name and type of primary insurance plan. The name and type
of secondary insurance plan was also included if the patient had
enrolled into one. Both primary and secondary insurance plans
were further categorized into government, commercial, and
charitable organizations.
The copay for primary and secondary insurance for each fill and
refill was recorded in the datasets.
The drug name was recorded during each fill and refill. Given
the focus of the study on CFTR modulator therapies, Orkambi,
Kalydeco and Symdeko records were identified in the datasets.
The date at which the prescription was filled or refilled for any
of the three CFTR modulator therapies.
Medication adherence to CFTR modulator therapies was
calculated using PDC as a measurement. The formula utilized
for calculating PDC is as follows:
 PDC= (Number of days in period “covered”/Number of
days in period)
The value of PDC ranged from 0 to 1, where 0 indicated an
adherence of 0% whereas 1 indicated 100% adherence. Given
the possibility of patients switching from one CFTR modulator

Age

Sex
Area of Residence
Allergy
Co-morbidity

Insurance
Characteristics

Co-pay
Drug Name

Fill Date
Medication
Adherence

47

Other Medications

therapy to another during the study period, a patient can have
two different PDC values for different medications.
The medications (other than CFTR modulator therapies) that the
patients take are self-reported in the database. The variable
includes the names of the medications which were further
utilized to estimate the burden of the disease.

Table 8: Categories of co-morbidities
Diseases
Infectious and parasitic diseases
Neoplasms
Endocrine, nutritional and metabolic diseases, and
immunity disorders, diseases of the blood and bloodforming organs
Mental disorders
Diseases of the nervous system and sense organs
Diseases of the circulatory system
Diseases of the respiratory system
Diseases of the digestive system
Diseases of the genitourinary system
Complications of pregnancy, childbirth, and the
puerperium
Diseases of the skin and subcutaneous tissue
Diseases of the musculoskeletal system and
connective tissue
Congenital anomalies
Certain conditions originating in the perinatal period
Symptoms, signs, and ill-defined conditions
Injury and poisoning
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ICD-9 codes
001-139
140-239
240-289

ICD-10 codes
A00-B99
C00-D009
D50-D89,
E00-E89

290-319
320-389
390-459
460-519
520-579
580-629
630-677

F01-F99
G00-H95
I00-I99
J00-J99
K00-K95
N00-N99
O00-O9A

680-709
710-739

L00-L99
M00-M99

740-759
760-779
780-799
800-999

Q00-Q99
P00-P96
R00-R99
S00-T88

Objective 2
To identify reasons for missed doses, medication discontinuation, and CFTR modulator
therapy-related adverse events
Responses regarding discontinuation, missing doses and adverse events associated
with the use CFTR modulator therapies extracted from patient assessments were
analyzed. Because the responses were collected over a span of over five years, there is a
probability that the same question could have been asked to the same patient at multiple
time points. Hence, the frequency was calculated using the number of responses as a unit
of measurement. The most frequent responses provided by the patients was identified for
each question.

Objective 3
To calculate medication adherence rate using PDC as a measure for patients with more
than one refill for CFTR modulator therapies and explore the association between
medication adherence rate and payer characteristics (those with and without secondary
insurance).
Fill dates for CFTR modulator therapies were utilized to calculate PDC for each
CFTR modulator therapy that a patient was on. Further, the overall PDC values for each
CFTR modulator therapy were categorized using age and insurance characteristics. Since
there is a possibility that during the entire study period (2015-2018) the patients may
enter, leave and then re-enter the system at different time points due to various reasons,
the calculated PDC may have some limitations. To overcome these limitations PDC was
also calculated for only one year (September 2017- August 2018) of the study period.
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Further, since there is a possibility of patients switching CFTR modulator therapies
during a year, PDC values were also calculated only for patients who haven’t switched
from one CFTR modulator therapy to the other in a year. These PDC values aided in
comparing the adherence of patients on different CFTR modulator therapies.

Objective 4
To analyze the spending pattern of the specialty pharmacy on CFTR modulator therapies
from 2015-2018.
Number of prescriptions dispensed every year for each CFTR modulator therapy
identified from the refill database were multiplied with the WAC (price obtained from the
Red Book) for each CFTR modulator therapy to calculate the spending of the specialty
pharmacy.

Objective 5
To identify the average co-pay of patients for CFTR modulator therapies based on payer
type.
Mean co-pay for each CFTR modulator therapy was calculated using co-pay
amount collected during the refill of medications. This was further categorized based on
patient’s insurance data (e.g., with or without secondary insurance). Further, mean values
of co-pay were also categorized using the type of insurance i.e. government, commercial
or charitable organizations for either primary or both primary and secondary insurances.
All values were inflated to the 2018 dollar values using Bureau of Labor Statistics data.
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Objective 6
To estimate the burden of medications (Other CF & non-CF medications) in the CF
population
Unique medications (except CFTR modulator therapies) reported by the patients
were identified from the databases. To estimate the burden of these medications, their
WAC values (lowest and highest) was obtained from the Red Book. The medications
were then grouped according to their therapeutic class and overall WAC values (lowest
and highest values) were estimated which provided the burden of these medications on
patients with CF.
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CHAPTER 4: RESULTS
OBJECTIVE 1
To describe the demographics, medication utilization, and insurance characteristics for
patients on CFTR modulator therapies.
Descriptive analyses were conducted using the last refill data of patients on CFTR
modulator therapies. A total of 4,444 unique patients were identified in the database from
2015-2018. This included 2,857 (64.29%) adults (age equal to or above 18 years) and
1,587 (35.71%) children/ adolescents (age less than 18 years).
Table 9 describes the demographic and medication utilization characteristics such
as age, sex, patient residence and CFTR modulator therapies for this population. The age
of the patients ranged from 1 to 88 years with a mean of 24.41±13.33 years. The sex
distribution of males and females was fairly even (p-value >0.05) across both age groups
(children/adolescents and adults) and in the overall sample. Conversely, a significant
difference was observed in the patient residence characteristics amongst
children/adolescents and adults (p=0.0007).
Based on the medication utilization characteristics, most patients were on
Orkambi (48.80%) followed by Kalydeco (28.00%) and Symdeko (23.20%). Also, a
statistical significance was also found in the difference in medication utilization
characteristics among children/adolescents and adults (p<0.00001).
Table 10 describes the insurance characteristics for the patients on CFTR
modulator therapies based on their last refill data. A majority of patients (62.85%) only
had primary insurance. Commercial insurance (52.88%) was the main type of primary
insurance with the rest having some form of government insurance (47.18%).

52

Table 9:Demographics and medical utilization characteristics of the patients (Based
on last refill data)
Variables
Age in years
Mean ± SD
Median

Overall
n=4444

Children/
Adolescents
n=1587

Adults

p-value

n= 2857
<0.0001

24.41 ± 13.33
22

11.80 ± 3.82
12

31.42 ± 11.43
29

Sex (n, %)
Female
2101, 47.28% 761, 47.95% 1340, 46.90%
Male
2343, 52.72% 826, 52.05% 1517, 53.10%
Patient Residence (n, %)
Northeast
839, 18.88%
263, 16.57% 576, 20.16%
Midwest
1199, 26.98% 452, 28.48% 747, 26.15%
South
1664, 37.44% 633, 39.89% 1031, 36.09%
West
742, 16.70%
239, 15.06% 503, 17.61%
CFTR Modulator Therapies
(n, %)
Kalydeco
1247, 28%
468, 39.49% 779, 27.27%
Orkambi
2167, 48.8%
904, 56.96% 1263, 44.21%
Symdeko
1030, 23.2%
215, 13.55% 815, 28.53%
Comparing children/adolescents versus adults using chi-square test
Significance p  0.05

0.57

0.0007

<0.00001

Table 10: Insurance characteristics of patients (Based on last refill data)
Insurance Type

Children/
Adolescents
n=1587
2793, 62.85% 1058, 66.67%

Adults
n=2857

Government

1316, 47.12% 578, 54.63%

738, 42.54%

Commercial

1477, 52.88% 480, 45.37%

997, 57.46%

Only Primary Insurance

Overall
n=4444

Primary and Secondary Insurance 1651, 37.15% 529, 33.33%
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1735, 60.73%

1122, 39.27%

Children/adolescents were mostly on government insurance (54.63%) while the adults
were on commercial insurance (57.46%). For patients with both primary and secondary
insurances, commercial (primary) and commercial (secondary) (80.57%) were the most
observed set of insurances (Refer Table 11).
Finally, the leading co-morbid condition in these patients was endocrine,
nutritional, metabolic and immunity disorders, diseases of the blood and blood-forming
organs (56.83%) (Refer Table 12). Most patients reported that they do not have any
known drug allergy (69.07%). All the co-morbidities and allergies are listed in the
Appendices III and IV, respectively.

OBJECTIVE 2
To identify reasons for missed doses, medication discontinuation, and CFTR modulator
therapy-related adverse events
The routine patient assessments collected by PCC were analyzed to explore the
reasons for missing doses and discontinuation of CFTR modulator therapies, and identify
adverse events related to these therapies. Patients reported switching of medications
(n=185, 74.90%) as the most frequent reason for discontinuing medications. Orkambi
(n=205, 62.69%) was reported to be discontinued the most. (Refer Tables 13 and 14).
Regarding patient responses to the question on missed doses in the past 28 days, a
majority of them taking Orkambi (n=24443, 92.23%) or Kalydeco (n=13985, 93.83%)
reported not missing any doses (Refer Table 15). Close to five percent of patients did
report missing one to five doses of both Orkambi and Kalydeco. The most frequent
reason for missing doses was forgetfulness for Kalydeco (n=366, 45.64%),
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Table 11:Insurance characteristics of patients on primary and secondary insurance (Based on last refill data)
Primary Payer Type

Secondary Payer Type
Overall
n=1651
Commercial

Government

Children/ Adolescents
Adults
n=529
n=1122
Commercial Government Commercial

Government

Commercial

1329, 80.57% 191, 11.57% 420, 79.40% 99, 18.71%

909, 81.02% 92, 8.20%

Government

110, 6.66%

102, 9.09%

21, 1.27%

8, 1.51%

2, 0.38%

19, 1.69%

Table 12: Top patient reported co-morbidities
Disease

Frequency
(n)
4770

Percent
(%)
56.83

Diseases of the respiratory system

1143

13.62

Infectious and parasitic diseases

563

6.71

Diseases of the digestive system

496

5.91

Symptoms, signs, and ill-defined conditions

375

4.47

Endocrine, nutritional and metabolic diseases, and immunity disorders, diseases of the blood
and blood-forming organs
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Table 13: Reasons for discontinuing medications
Question

Why was the medication discontinued?

Response

Frequency
n=247
Switched medication
185
Other (document in comments section below) 23
Uncertain
22
Side effects
12
Lab abnormalities
2
Administration difficulties
1
Allergic reaction
1
Financial issues
1

Percent (%)
74.90
9.31
8.91
4.86
0.81
0.40
0.40
0.40

Sample size only included responses to this specific question

Table 14: Discontinued medications
Question

Patient's medication(s) that is/are being discontinued

Response

Frequency
n=327
62
205
10
50

Kalydeco
Orkambi
Symdeko
Non-CFTR modulator therapies

Percent (%)
18.96
62.69
3.06
15.29

Sample size only included responses to this specific question

Table 15: Frequency of missing doses
Question

Response

In the past 28 days, how many
doses of your Orkambi would you
say you missed or skipped?

Frequency
n=25840
0
24443
1 to 5
1273
6 to 11
55
12 or more
69
Not filling drug today 509
Unsure
153

Percent (%)
92.23
4.80
0.21
0.26
1.92
0.58

Sample size only included responses to these specific question
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In the past 28 days, how many
doses of your Kalydeco would
you say you missed or
skipped?
Frequency
Percent (%)
n=14905
13985
93.83
686
4.60
47
0.32
33
0.22
150
1.01
4
0.03

Orkambi (n=688, 59.98%) and Symdeko (n=29, 53.70%). Some patients on Kalydeco (n=157,
19.58 %), Orkambi (n=222, 19.35%) and Symdeko (n=6, 11.11%) even responded that “they
were too busy” or “were unable to fit it into their daily routine” as a reason for missing doses
(Refer Table 16). Majority of patients on Kalydeco (n= 8947, 96.36%), Orkambi (n=13531,
93.48%) or Symdeko (n=1412, 82.96%) did not report any adverse events associated with the
three therapies (Refer Table 17).
OBJECTIVE 3
To calculate medication adherence rate using PDC as a measure for patients with more than one
refill for CFTR modulator therapies and explore the association between medication adherence
rate and payer characteristics (those with and without secondary insurance).
PDC was calculated for the following time periods—entire study period (January 2015August 2018), one year (September 2017- August 2018) and for patients who did not switched
from one CFTR modulator therapy to another in one year (September 2017- August 2018). PDC
was calculated for both the age groups (children/adolescents and adults) and insurance
characteristics (those with only primary insurance and those with both primary and secondary
insurances). Overall, the average PDC values exceeded the threshold of 0.8 except for adults on
Orkambi over the entire study period (0.79). Also, it was seen that overall and across all
categories (age and insurance characteristics), Symdeko had the highest PDC (>0.91) when
compared to other CFTR modulator therapies.
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Table 16: Reasons for missing doses
Question
Response

What causes you to
miss your Kalydeco?
Frequency Percent
n= 802
(%)
366
45.64
157
19.58
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Forgetfulness
Too busy/Unable to fit into daily
routine
Vacation/Away from home
34
4.24
Insurance issues (Prior Auth)
36
4.49
Infection/Illness
32
3.99
Surgery
11
1.37
Financial issues
4
0.50
Administration difficulties
2
0.25
Side effects
2
0.25
Dose or frequency changed
3
0.37
Other (document in comments
117
14.59
section below)
Lapse in access or waiting for
38
4.74
delivery
Sample size only included responses to these specific question

What causes you to miss
your Orkambi?
Frequency Percent (%)
n= 1147
688
59.98
222
19.35

What causes you to miss
your Symdeko?
Frequency
Percent
n= 54
(%)
29
53.70
6
11.11

81
76
38
12
11
7
7
5

1
1

1.85
1.85

2
1

3.70
1.85

13

24.07

1

1.85

7.06
6.63
3.31
1.05
0.96
0.61
0.61
0.44

Table 17: Adverse events reported for CFTR modulator therapies
Question

What side effects, if any,
are you experiencing with
your Kalydeco?

Response

Frequency
n= 9823
8947
156
97

Percent
(%)
96.36
1.68
1.04

27
12
10
6

0.29
0.13
0.11
0.06

6

None
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Not filling drug today*
Other (document in comments section
below)
Headache
Rash
Upper respiratory tract infection
Oropharyngeal pain (mouth or throat
discomfort)
Symptoms of liver problems (dark urine,
loss of appetite, stomach pain or
discomfort, unusual nausea or vomiting,
yellowing of the skin or eyes)
Nasopharyngitis (cold symptoms, runny
nose, sneezing)
Nasal congestion
Chest tightness
GI symptoms (nausea, diarrhea, gas)
Dyspnea (shortness of breath)
Fatigue
Menstrual problems (irregular, missed or
abnormal periods or increase in the
amount of bleeding)

What side effects, if
any, are you
experiencing with
your Orkambi?
Frequency Percent
n= 14474
(%)
13531
93.48
537
3.71
152
1.05

7

0.05

0.06

9

0.06

5

0.05

13

0.09

3

0.03

13

0.14

75
54
52
24
16

0.52
0.37
0.36
0.17
0.11

What side effects, if any,
are you experiencing
with your Symdeko?
Frequency
n= 1699
1412
197
57

Percent
(%)
82.96
11.57
3.35

16

0.94

1

0.06

10

0.59

Muscle Pain
4
0.03
Vision changes
1
0.01
2
0.12
Dizziness
4
0.24
*During regular follow ups, the system provides the PCC the option to enter this response if the patient is not filling any
particular medication while the assessment
Sample size only included responses to these specific question
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For the entire study period, a total of 4569 PDC values were calculated. This number is
higher than the number of unique patients (4444) as some patients had switched from one CFTR
modulator therapy to another resulting in more PDC values than the study sample. The overall
PDC for the entire study period for all CFTR modulator therapies was 0.83. The average PDC
over the one-year period (n=3482) was 0.87 and among patients who did not switch from one
CFTR modulator therapy to another in this one-year period was 0.86 (Refer Tables 18, 19 and
20).
Among patients who did not switch medications over a one-year period (September
2017- August 2018), it was observed that children/ adolescents on Orkambi (p-value=0.0001)
and Symdeko (p-value=0.001) had significantly higher PDC values when compared to adults.
Across both the insurance characteristics of patients who did not switch medications in a year
(September 2017- August 2018), no particular pattern emerged, and it was seen that the PDC
was majorly similar with some marginal differences.

OBJECTIVE 4
To analyze the spending pattern of the specialty pharmacy on CFTR modulator therapies from
2015-2018.
The spending patterns of the specialty pharmacy was estimated based on the number of
prescriptions dispensed each year for each CFTR modulator therapy and WAC pricing adjusted
to 2018-dollar values using the Bureau of Labor Statistics data. Amongst the CFTR modulator
therapies, an upward trend was observed in the spending on Orkambi which rose from $67
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Table 18: PDC calculated using fill dates from the entire study period (2015- August 2018)
(A) Overall PDC
Overall
n
Total
4569
Kalydeco 1225
Orkambi 2479
Symdeko 865

Mean ± SD
0.83 ± 0.18
0.81 ± 0.18
0.81 ± 0.18
0.92 ± 0.11
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(B) PDC categorized according to age
Children/ Adolescents
n
Mean ± SD
Total
1596
0.85 ± 0.16
Kalydeco
450
0.83 ± 0.16
Orkambi
968
0.84 ± 0.16
Symdeko
178
0.94 ± 0.11

Adults
n
2973
775
1511
687

(C) PDC categorized according to insurance characteristics
Individuals with only Primary Insurance
Total
Kalydeco
Orkambi
Symdeko

n
2838
727
1598
513

Mean ± SD
0.83 ± 0.17
0.81 ± 0.18
0.81 ± 0.18
0.92 ± 0.11

Mean ± SD
0.82 ± 0.18
0.80 ± 0.19
0.79 ± 0.19
0.92 ± 0.11

Individuals with Primary and Secondary Insurance
n
1731
498
881
352

Mean ± SD
0.83 ± 0.18
0.82 ± 0.19
0.80 ± 0.19
0.92 ± 0.10

Table 19: PDC calculated using fill dates for one year (September 2017- August 2018)
(A) Overall PDC
Overall
n
Mean ± SD
Total
3482 0.87 ± 0.14
Kalydeco
850
0.85 ± 0.15
Orkambi
1767 0.85 ± 0.14
Symdeko
865
0.92 ± 0.11
(B) PDC categorized according to age
Children/ Adolescents
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Total
Kalydeco
Orkambi
Symdeko

n
1309
338
793
178

Mean ± SD
0.87 ± 0.14
0.85 ± 0.15
0.86 ± 0.13
0.94 ± 0.11

Adults
n
2173
512
974
687

Mean ± SD
0.86 ± 0.14
0.84 ± 0.16
0.83 ± 0.15
0.92 ± 0.11

(C) PDC categorized according to insurance characteristics
Individuals with only Primary
Individuals with Primary and
Insurance
Secondary Insurance
n
Mean ± SD
n
Mean ± SD
Total
2110
0.87 ± 0.14
1372
0.87 ± 0.14
Kalydeco
482
0.84 ± 0.16
368
0.85 ±0.15
Orkambi
1115
0.85 ± 0.14
652
0.84 ± 0.14
Symdeko
513
0.92 ± 0.11
352
0.92 ± 0.10

Table 20: PDC calculated for all patients who did not switched medications in one year (September 2017- August 2018)
(A) Overall PDC
Overall
n
Mean ± SD
Total
2548 0.86 ± 0.15
Kalydeco 789 0.84 ± 0.16
Orkambi 1361 0.84 ± 0.15
Symdeko 398 0.92 ± 0.11
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(B) PDC categorized according to age
Children/ Adolescents Adults
n
Mean ± SD
n
Mean ± SD
Total
1075 0.86 ± 0.14
1473 0.85 ± 0.15
Kalydeco 330
0.85 ± 0.15
459 0.84 ± 0.16
Orkambi 684
0.86 ± 0.14
677 0.83 ± 0.15
Symdeko 61
0.96 ± 0.10
337 0.91 ± 0.11
Comparing children/adolescents versus adults using t-test
Significance p  0.05

p-value
0.0876
0.3744
0.0001
0.001

(C) PDC categorized according to insurance characteristics
Individuals with only Primary
Individuals with Primary and
p-value
Insurance
Secondary Insurance
n
Mean ± SD
n
Mean ± SD
Total
1564
0.86 ± 0.15
984
0.86 ± 0.15
1.00
Kalydeco 455
0.84 ± 0.16
334
0.84 ± 0.16
1.00
Orkambi 869
0.85 ± 0.15
492
0.84 ± 0.15
0.24
Symdeko 240
0.92 ± 0.12
158
0.92 ± 0.11
1.00
Comparing individuals with only primary insurance versus individuals with primary and secondary insurance using t-test
Significance p  0.05

million in 2015 to $281 million in 2017. However, the spending on Kalydeco remained
fairly constant over the years with $103 million spent in 2015 to $119 million in $2017.
Additionally, the introduction of Symdeko did not offset the specialty pharmacy’s
spending on Orkambi ($183 million) and Kalydeco ($114 million) till August 2018
(Refer Table 21 and Figure 7).

OBJECTIVE 5
To identify the average co-pay of patients for CFTR modulator therapies based on payer
type.
Average co-pay was calculated for all CFTR modulator therapies from January
2015- August 2018 across all insurance characteristics. A non-linear trend was observed
for the average co-pay of all CFTR modulator therapies over this time period (Refer
Figure 8). While the co-pay for Kalydeco increased from $247.14 in 2015 to $292.36 in
2017, there was a drop in co-pay for Orkambi in 2016 followed by an increase to $173.35
in 2017. It was also observed that the average co-pay for 2018 was the highest among all
the years across all CFTR modulator therapies.
A huge range was observed in the co-pay values were observed for all CFTR
modulator therapies across all years (Refer Table 22). The highest range was observed in
2015 for Orkambi where the minimum co-pay value was $0 while the maximum was
$33309.57. For patients with only primary government insurance, the average co-pay
ranged from $0-$40 and for those on commercial insurance, it ranged from $20-$310
(Refer Table 23). Patients on government insurance and using Kalydeco had an average
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Table 21: Number of prescriptions of CFTR modulator therapies dispensed by the specialty pharmacy in a year
CFTR Modulator
2015
2016
therapy
Kalydeco
4347
4899
Orkambi
3223
9642
Symdeko
*Number of prescriptions calculated only till August 2018
Symdeko launched in 2018

2017

2018*

4999
13449
-

4794
8763
3842

Table 22: Range of co-pay

All drugs

Range of Co-pay
Kalydeco
Orkambi

Symdeko

Min Max

Min Max

Min Max

Min Max

66

2015 $0

$33309.57 $0

$27754.95 $0

$33309.57

2016 $0

$25517.72 $0

$25517.72 $0

$21049.72

2017 $0

$23825.14 $0

$23825.14 $0

$22745.96

2018 $0

$24494.49 $0

$24494.49 $0

$22339.76 $0

$22822.37

Table 23: Co-pay for people on only primary insurance
Kalydeco

2015
2016
2017
2018

Government
$3.82
$2.31
$16.82
$12.21

Orkambi
Commercial
$309.42
$297.13
$197.58
$160.75

Overall
$184.68
$156.05
$109.20
$87.31

Government
$10.88
$0.80
$1.76
$0.55

Symdeko
Commercial
$25.63
$19.98
$124.16
$146.06

Overall Government Commercial Overall
$20.20
$10.63
$60.30
$66.41 $38.14
$203.84
$135.18

Figure 7: Spending pattern of the specialty pharmacy

Spending on CFTR Modulator Therapies
$300,000,000

Total Spending

$250,000,000
$200,000,000
$150,000,000

Orkambi

$100,000,000

Kalydeco

$50,000,000
$0
Orkambi
Kalydeco

2015
$67,422,678
$103,876,477

2016
$201,703,216
$117,067,141

Year
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2017
$281,342,724
$119,456,754

Figure 8: Trends in average co-pay

Trends in average co-pay
$450.00
$400.00
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Co-pay (in USD)

$350.00
$300.00
$250.00

$200.00

Kalydeco
Orkambi

$150.00

Symdeko

$100.00
$50.00
Kalydeco
Orkambi
Symdeko

2015
$247.14
$183.42

2016
$271.65
$136.53

2017
$292.36
$173.35

Year
*Calculated using data till August 2018

2018*
$396.00
$302.01
$233.16

co-pay of $12.21 in 2018 compared to those on commercial insurance whose copay was
$160.75 in 2018. Similarly, for patients on government insurance, the average co-pay for
Orkambi was $0.55 in 2018 while for those on commercial insurance, it was $146.06 in
2018. With the introduction of Symdeko in 2018, the average co-pay for patients on
government insurance was $38.14 and for those on commercial insurance, it was
$203.84. (Refer Table 23).
For patients who had both primary and secondary insurances, the secondary copay over all the years (January 2015-August 2018) ranged from $0-$35. Patients whose
primary and secondary insurances were commercial in nature had a similar co-pay for all
three CFTR modulator therapies and it ranged from $12-$22. The average co-pay in 2018
for all CFTR modulator therapies for patients enrolled in government primary and
secondary insurances was observed to be $0 (Refer Table 24).

OBJECTIVE 6
To estimate the burden of medications (CF related & non-CF related medications) in the
CF population
To estimate the overall burden of medications on patients with CF, all the
medications (other than CFTR modulator therapies) listed under the patients’ names were
categorized into therapeutic areas and a total value was calculated based on the WAC
costs from the 2018 Red Book. The therapeutic categories were created by combining
medications in similar therapeutic class. For example, antidepressants, antiepileptics and,
anxiolytics were categorized under the therapeutic category of CNS and mental health. A
total of 10,838 medications were recorded in the database and these were combined into
14 therapeutic categories. The most widely reported therapeutic class included anti-
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Table 24: Co-pay for people on primary and secondary insurance
(A) Primary Insurance - Commercial & Secondary Insurance – Commercial

Kalydeco
Orkambi

2015
Primary
Co-pay
$321.97
 $1837
$564.3 
$2731

Secondary
Co-pay
$22.89 
$137.06
$14.56 
$5.64

2016
Primary
Co-pay
$407.25 
$1499
$320.98 
$991.10

Secondary
Co-pay
$13.72 
$5.00
$13.18 
$5.51

2017
Primary
Co-pay
$583.51 
$1705
$409.35 
$1463

Secondary
Co-pay
$12.9  $5.49
$18.08 
$352.15

Symdeko

2018
Primary Copay
$747.41 
$2105
$603.05 
$1929
$372.78 
$1910

Secondary
Co-pay
$21.95 
$226.45
$15.17 
$135.91
$13.41 
$34.82

2018
Primary Copay
$400.01 
$1403
$659.44 
$2523
$84.69 
$299.71

Secondary
Co-pay
$0.15 
$0.74
$0.11 
$0.57
$0.11 
$0.59

(B) Primary Insurance - Commercial & Secondary Insurance – Government
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Kalydeco
Orkambi
Symdeko

2015
Primary
Co-pay
$208.13
 $1937
$468.43
 $1407

Secondary
Co-pay
$0.33 
$2.25
$3.66 
$40.42

2016
Primary
Co-pay
$239.22 
$899.05
$509.67 
$1571

Secondary
Co-pay
$0.1 
$0.53
$0.08 
$0.51

2017
Primary
Co-pay
$336.4 
$1227
$343.34 
$1709

Secondary
Co-pay
$0.24  $1.05
$0.22  $0.8

(C) Primary Insurance - Government & Secondary Insurance - Government

Kalydeco

Orkambi

2015
Primary
Co-pay
$1016.45

$508.69
$145.69

$373.14

Secondary
Co-pay
$16.03 
$19.68
$0  $0

2016
Primary
Co-pay
$1591.47 
$1136
$218.65 
$1020

Secondary
Co-pay
$9.96 
$17.44
$0  $0

2017
Primary
Co-pay
$969.77 
$859.89
$238.5 
$523.35

Secondary
Co-pay
$4.12 
$12.25
$0.25  $0.83

Symdeko

2018
Primary Copay
$837.33 
$928.80

Secondary
Co-pay
$0  $0

$610.29 
$1050

$0  $0

$266.6 
$486.59

$0  $0

(D) Primary Insurance - Government & Secondary Insurance – Charitable Organizations
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Kalydeco

Orkambi
Symdeko

2015
Primary
Co-pay
$1159.45

$490.33
$962.00

$621.90

Secondary
Co-pay
$17.37 
$126.18

2016
Primary
Co-pay
$1146.48 
$946.92

$4.62 
$5.83

$843.67 
$863.17

Secondary
Co-pay
$34.23 
$184.61

2017
Primary
Co-pay
$799.24 
$925.22

Secondary
Co-pay
$4.51  $6.86

2018
Primary Copay
$1153.97 
$967.31

$3.85 
$7.07

$429.97 
$692.20

$7.66 
$35.96

$595.54 
$921.43

0.8  3.37

$858.87 
$555.63

$15.9 
$110.86

Secondary
Co-pay
$45.36 
$216.5

14 therapeutic categories. The most widely reported therapeutic class included anti-infectives
(22.81%), respiratory (20.23%), and electrolytes and dietary supplements (15.69%) (Refer Table
25). The most frequently listed medications were antibiotics (20.95%), anti-inflammatory
(12.70%) and bronchodilators (11.47%) (Refer Table 26).
The economic burden of these medications was calculated using the lowest and highest
WAC value obtained from the Red Book. Across all the medications the lowest WAC was
observed for an iron supplement ($0.2) while the highest was for an ovulation stimulant
($98,175) (Refer Table 26). Similarly, the categories created had a wide range due to a variation
in costs, which was based on different strength and package sizes. Though anti-infectives had the
highest utilization as reported by their frequency of use, their cost ranged from $0.58 to
$8,009.77. Respiratory medications had a similar range from $0.64 to $8,127.50. The broadest
range was observed for medications categorized in endocrine and sexual health, with a low of
$1.12 to a high of $98,175.
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Table 25: Overall economic burden of different therapeutic categories in patients with CF
Categories
Anti-infectives

Frequency Percent
(n)
(%)
2472
22.81

Low Cost
(in $)*
0.58

High Cost
(in $)*
8009.77

Respiratory

2192

20.23

0.64

8127.50

Electrolytes and dietary supplements 1701

15.69

0.20

63592.75

Analgesics

1454

13.42

0.71

15522.32

Enzyme replacement

894

8.25

74.30

2339.79

Gastrointestinal agents

834

7.70

0.49

33955.80

CNS and mental health

444

4.10

1.35

32336.16

Endocrine and sexual health

368

3.40

1.12

98175.00

Cardiovascular

161

1.49

0.40

59433.91

Miscellaneous

132

1.22

3.52

8210.64

Medical device

118

1.09

3.23

140.23

Blood

41

0.38

0.38

9297.70

Dermatological

22

0.20

0.27

22004.61

5

0.05

1.39

451.19

Ophthalmic
*2018 WAC obtained from Red book
CNS- Central Nervous System
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Table 26: Burden of medications under each therapeutic class in patients with CF
Therapeutic Class
Analgesics
Anti-inflammatory
Analgesic
Antipyretic
Anti-infectives
Antibiotic
Antifungal
Antiviral
Viral Vaccine
Antimalarial
Antitubercular
Antimicrobial
Anti-Hepatitis C
Blood
Anticoagulant
Antifibrinolytic
Antianemia
Antiplatelet agent
Cardiovascular
Antihypertensive
Antihyperlipidemic
Diuretic
Antihypertriglyceridemic
CNS and mental health
Antidepressant
Antiepileptic
Anxiolytic
CNS stimulant
Anti-ADHD
Antipsychotic
Skeletal muscle relaxant
Hypnotic
ADHD agent
Antimigraine
Mood stabilizers

Frequency Percent
(n)
(%)

Low Cost
(in $)

High Cost
(in $)

1376
64
14

12.70
0.59
0.13

0.79
0.71
3

15522.32
8080.91
319.66

2271
75
66
44
7
5
4
1

20.95
0.69
0.61
0.41
0.06
0.05
0.04
0.01

1.43
0.58
11.31
168.2
16.25
37.99
3.73
695.6

8009.77
6166.39
2889.36

32
6
2
1

0.30
0.06
0.02
0.01

0.38
9
165.8
580.09

14932.9
2794.98
9297.7

107
48
3
2

0.99
0.44
0.03
0.02

0.4
0.86
1.65
299.35

11181.24
59433.91
584

167
54
58
42
38
25
18
13
10
8
5

1.54
0.50
0.55
0.39
0.35
0.23
0.17
0.12
0.09
0.07
0.05

1.35
1.7
1.99
18
85
10
7.75
4.61
63.27
14.75
6.48

1985
28235.53
32336.16
1811.25
1012.8
9522.8
5083.37
4023.44
1459.5
952.2
788
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1553.25
130
60.5

Antiparkinson
4
Antimuscarinic
2
Dermatological
Antiacne
15
Keratolytic
3
Antiseptic
2
Antipruritic
1
Antipsoriatic
1
Electrolytes and dietary supplements
Multivitamin
597
Calcium supplement
376
Sodium supplement
367
Nutritive agent
197
Probiotic
66
Iron supplement
42
Electrolyte supplement
38
Fluoride supplement
7
Potassium supplement
5
Calcium regulator
3
Folic acid supplement
3
Enzyme replacement
Enzyme replacement
894
Gastrointestinal agents
Gastric acid suppressant
591
Laxative
156
Antiemetic
36
Antacid
22
Antidiarrheal
11
Prokinetic
10
Antiulcerative
5
Antispasmodic
2
Antiflatulent
1
Endocrine and sexual health
Antidiabetic
218
Contraceptive
64
Endocrine-metabolic
28
agent
Antihypothyroidism
33
Antiosteoporotic
7

0.04
0.02

99.29
72.13

744.83
484.77

0.14
0.03
0.02
0.01
0.01

5.85
5.74
0.53
0.27
1600

3104.51
3540
15300

5.51
3.47
3.39
1.82
0.61
0.39
0.35
0.06
0.05
0.03
0.03

1.18
0.97
1.62
1.18
2.59
0.2
0.94
3.78
0.5
340.98
503.07

63592.75
1486.82
250
5876.01
85
53.16
2.1
796.47
2258.5
2437.85

8.25

74.3

2339.79

5.45
1.44
0.33
0.20
0.10
0.09
0.05
0.02
0.01

1.89
0.76
0.58
0.49
1.2
310.94
3.82
19.49
1.89

8363.89
8606.25
33955.8
10.5
1254.66

2.01
0.59
0.26

1.12
7.54
6.5

1705
15040
13200

0.30
0.06

32.77
3.5

868.5
158.37
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22004.61

938.25
3195.49
5.82

Testosterone replacement
Benign prostatic
hypertrophy agent
Ovulation stimulant
Estrogen replacement
Erectile dysfunction agent
Medical Device
Medical device
Miscellaneous
Anti-biliary cirrhosis
Immunosupressant
Antineoplastic
Antirheumatic
Anesthetic
Antioxidant
Anti-gout
Anti-renal tubular
acidosis
Anti-Multiple sclerosis
Anti-relapse
Antiobesity
Uricosuric
Ophthalmic
Ophthalmologic agent
Antiglaucoma
Miotic
Respiratory
Bronchodilator
Antiasthma
Antihistamine
Decongestant
Expectorant
Mucolytic
Antitussive

5
4

0.05
0.04

18
4.99

640.39
2208.86

4
3
2

0.04
0.03
0.02

68.55
26.94
2121.53

98175
4271.25
7071.56

118

1.09

3.23

140.23

84
12
10
7
6
5
3
1

0.78
0.11
0.09
0.06
0.06
0.05
0.03
0.01

140
32.98
3.52
3.92
12
3.95
7.96
152.62

5735.89
3016.22
1367.66
5174.06
545.11
17.31
541.53

1
1
1
1

0.01
0.01
0.01
0.01

2691.87
8210.64
42.93
59.44

81.2
2895

3
1
1

0.03
0.01
0.01

1.39
51.05
40

451.19
131.5
166.83

1243
547
347
18
16
11
10

11.47
5.05
3.20
0.17
0.15
0.10
0.09

3.75
12
0.64
1.56
0.98
29.91
10.71

8127.5
1084.66
848.25
65.42
182.93
752
3641.43
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CHAPTER 5: DISCUSSION
This chapter provides the study findings, draws conclusions, presents study implications,
lists limitations for each phase of the study, and provides recommendations for future
research.

PART I
CFTR modulator therapies have revolutionized the treatment of CF by improving
production, intracellular processing, and/or function of the defective CFTR protein. This
has resulted in better symptom management and also affected the disease progression.
Similar to other chronic conditions, adherence to CFTR modulator therapies is essential
in maximizing the clinical benefit.65 Prior research in CF has mainly focused on
calculating adherence for pulmonary medications, nebulizers, and multivitamins.

33,66

CFTR modulator therapies are available in the market since 2012 and still, there is a lack
of information regarding patient adherence to these medications. The study utilized a
national specialty pharmacy refill database to assess the utilization of CFTR modulator
therapies in a CF population including patient adherence.
The CF Foundation collects data annually from a nationwide network of more
than 120 CF Foundation accredited centers and provides a data summary in the form of a
registry report which contributes to clinical trial design, real-world research including
safety and effectiveness studies of newly approved therapies, and quality improvement.
The CF Foundation registry report serves as a good reference to understand the
demographic representation of the AllianceRx Walgreens specialty pharmacy patient
population used in this study. The 2017 CF Foundation registry reports a total of 29,887
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patients suffering from CF residing in the US 24 while a total of 4,444 (14.87%) patients
were utilized for this study. It was observed that the mean age of patients in the study
(24.41 years) was higher than that reported by the CF Foundation in 2017 (21.7 years).
The reason for this could be that a higher proportion of adults (64%) were present in the
AllianceRx Walgreens specialty database in comparison to 53.5% of the adults in the CF
Foundation registry. In terms of gender distribution, both the CF Foundation registry and
the study population were similar with higher number of males being present compared
to females.
All the patients included in the study had some type of insurance coverage. Public
health insurance programs are government-funded and provide health care assistance to
qualifying individuals and their families. These programs include Medicare, Medicaid
and Children's Health Insurance Program (CHIP). Many states also have CF-specific
programs such as programs for children with special health care needs (CSHCN
programs) which provide services such as medically necessary health care, and support
services including respite care (care provided by others). In most states, families that do
not qualify for Medicaid may be eligible for this program, while some states require
enrollment in Medicaid to qualify.67 With so many coverage options provided by the
government, it was observed that a majority of children/adolescents (54.63%) in the study
had a primary government health insurance. In adults, a majority of patients (57.46%)
were on commercial insurance which could have been provided by their employer or
purchased by the individual.
Ronan et al. provided a comprehensive list of co-morbidities associated with CF
which included pulmonary, pancreatic disease, hepatobiliary disease, GIT disorders,
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kidney disease, genitourinary, bone, coronary artery disease, anxiety, depression and
others.68 Many of these conditions have been reported by patients in the study. However,
one of the biggest discrepancies is the difference between prevalence reported in the
literature and self-reporting frequency of the conditions found in the study. For example,
anxiety and depression affect 8-33% of patients suffering from CF 24 but the prevalence
was 1.25% in the study. It is difficult to pin point the reasons for this difference, however,
it could be attributed to underreporting given that the study relied on patient self-reports.
There are a number of potential factors that contribute to medication nonadherence. Understanding problems that patients face that lead to discontinuation,
missing of medications or suffering from an adverse reaction can help in tailoring
treatment and guidance for patients, thereby improving adherence. Trimble et al. reported
that the discontinuation of Kalydeco leads to rapid deterioration of patient's lung function
and symptoms.69 Our study revealed that the most common reason for discontinuing
medication was switching which indicates that at least patients were switched to some
other therapy, which could have helped manage their symptoms. The most frequently
reported discontinued therapy was Orkambi which was the most utilized therapy by
patients in the study. Adverse events that were reported by patients during routine
assessments were also in accordance with the ones reported in the clinical trials of these
treatments.70–72
A recent study by Eakin et al. indicated that nonadherence in patients with CF is
associated with increased hospitalizations and longer length of stays due to pulmonary
exacerbations and lower baseline lung function.31 However, none of the published studies
have calculated or reported adherence of patients to CFTR modulator therapies. This
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study calculated PDC values as a measure of adherence. It is universally accepted that
PDC values above 0.80 or 80% indicates that the patients are adherent to the treatment. In
the study, PDC values were calculated for three different time periods to overcome the
limitations of patients switching medications and also exiting and entering the Walgreens
system. Except for the PDC value (0.79) in adults on Orkambi, all other PDC values
across all categorizations exceeded the threshold of 0.80. Symdeko had the highest PDC
values amongst all medication, which could be due to the availability of refill data for a
shorter time period (launched in 2018) in comparison to Orkambi and Kalydeco.
Generally, the availability of refill data for a shorter period of time lowers the chances of
missed doses resulting in higher PDC values.
Comparing the PDC values of children/adolescent to adults for Orkambi and
Symdeko revealed that children/adolescent had a significantly higher PDC value than
adults. Parental monitoring and timely refilling of medications could be some reasons for
the higher PDC values. Supporting evidence for adherence to CFTR modulator therapies
was found in self-reports of patients where majority of them reported not missing any
doses. Sawicki et al. reported that patients with CF on an average spend 108 minutes per
day on treatments, which include at least three inhaled and three oral therapies.73 Hence,
it is understandable that sometimes people forget or are too busy to take the medications
resulting in missed doses.
In comparison to previously reported medication adherence of 50% in patients
with CF, the patients enrolled in this study showed a higher adherence rate. The CF care
program initiated by AllianceRx Walgreens specialty pharmacy provides timely
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reminders for refilling medications and provides guidance to patients on a variety of
topics, which may have contributed to increased adherence in patients.

PART II
CFTR modulator therapies play an important role in CF management. However,
with the high acquisition cost (reported as WAC) of Kalydeco, Orkambi and Symdeko
being $272,886, $311,719 and $292,258, respectively, a significant economic burden is
placed on both patients and payers. Grosse et al. observed that in 5.8% of patients with
CF in the US who took ivacaftor in 2016, the drug accounted for 85% of their
pharmaceutical spending while for lumacaftor/ivacaftor, taken by 17.6% of the CF
population, accounted for 74% of their total pharmaceutical spending.26 To provide
further information regarding the economic burden of CFTR modulator therapies, the
current study aimed to quantify the spending of the AllianceRx Walgreens specialty
pharmacy and the burden of co-pay on patients related to CFTR modulator therapies.
Another objective of this study was to provide an estimate of the economic burden of
medications consumed by patients along with CFTR modulator therapies. There is
currently no information available on the cost burden of medications for comorbid
conditions in CF.
Study results showed an upward trend in the CFTR modulator therapies spending
by the specialty pharmacy. The reasons for increase in spending could be twofold:
increased utilization and increased unit cost. Since the methodology accounted for the
increase in unit cost by utilizing the same WAC to calculate spending across all the years,
the most probable reason for this increase in spending could be the increase in utilization
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of CFTR modulator therapies. Over the study period, more patients possibly were
prescribed these CFTR modulator therapies based on their superior clinical evidence.
Also, FDA has expanded the indications for the CFTR modulator therapies over time. For
example, in 2015 Orkambi was approved only in patients above 12 years of age whereas
in 2018, it was approved for patients above the age of 2 years.74 Over the study period,
such approvals might have lead a larger population being eligible for the medications
which could have resulted in increased utilization of CFTR modulator therapies and
subsequent increase in specialty pharmacy spending.
The National Institute of Health defines copay as the amount of money that a
patient with health insurance pays for each healthcare service, such as a visit to the
doctor, laboratory tests, prescription medicines, and hospital stays. 75 The amount of
copay usually depends on the type of healthcare service and is decided by the insurance
provider. In theory, copayments were intended to reduce drug expenditure in insured
population by reducing moral hazard associated with medicines supplied at reduced or
zero cost. That is, copayments dis-incentivizes the collection of medicines that patients
do not consume, or which have no role in improving health thus reducing waste.
However, the co-pays are also said to be a barrier (possibly due to unaffordability)
resulting in a decrease in use of medications.76
Since there is no information available regarding the co-pay for medications in CF
like the CFTR modulator therapies, this study aimed to provide some insight on the same.
The range for co-pay across all the years was observed to be extremely broad with the
lowest copay being $0 and highest being $33,309.57. It can be assumed that the patients
who might have paid such high co-pays may have received either negligible or no support
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from their insurance providers. The wide range of co-pays could be attributed to
differences in insurance and provider characteristics. Also, since the co-pay is decided by
the insurance providers, no specific trends were observed across all the years.
Average co-pay was categorized using insurance characteristics for each CFTR
modulator therapy. Due to subsidies offered by the government for Medicare, Medicaid,
and other federal and state funded assistance programs for healthcare, the co-pay of
patients on such primary health insurances were much lower ($0-$30) than patients on
commercial health insurance ($25-$310). Additionally, secondary health insurance helps
in covering a lot of out-of-pocket costs, thus, the secondary co-pay for patients was low
depending on the type of primary and secondary insurance.
Previous literature has associated co-pays with non-adherence especially in
vulnerable populations (e.g., older people and those on low or fixed incomes) with
increased sensitivity to adverse health outcomes.76 However, in our study no significant
differences were observed in adherence of patients were on primary versus those who
were on primary + secondary insurance even though the co-pay differed for both of these
populations. This could be because of the chronic nature of CF and the need to consume
daily medications for symptom management.
CF is a complex disease affecting various organs in the body. Numerous
medications are essential in managing various symptoms and complications in patients.
Grosse et al. estimated the increase in pharmaceutical spending from 2010-2016 but
didn’t provide an estimation for the therapeutic classes and their individual costs.26
Cumulatively, these medications can cause a significant economic burden and hence, it
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was essential to assess the cost of each therapeutic class and how much they contribute to
the overall burden of CF.
This was one of the first studies that tried to estimate the utilization and economic
burden associated with the medications that are being prescribed to CF patients. The
study revealed that the most common reported medications were anti-infectives,
respiratory, and electrolyte and dietary supplements. This is in accordance with the
literature as National Institute of Health has stated that the most serious and common
complications of CF are problems with the lungs, also known as pulmonary or respiratory
problems, which may include serious lung infections. Patients with CF also have
problems maintaining good nutrition, because of the difficulty in absorbing the nutrients
from food.3
Due to the variation in dosage strengths and the package sizes, a range was
estimated for each therapeutic class. Out of the most common therapeutic areas,
electrolytes and dietary supplements have the broadest range with multivitamins being
the most expensive ($63,592.75) and iron supplements (0.20) being the least expensive.
Such a broad range can also be attributed to differences in package sizes.
This analysis sheds light on different medications that the patients are utilizing.
The 2017 CF Foundation registry report highlighted the prevalence of mental health
issues such as depression and anxiety in patients with CF. Analysis of the utilization data
shows that many patients have reported the use of CNS and mental health products.
Along with utilization, this study also highlights the economic burden of medications on
the patients. Since these medications are utilized along with CFTR modulator therapies,
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the high cost of CFTR modulator therapies along with the cost of other medications can
cause a substantial economic burden for the patients.
The 2013 National Health Interview Survey found that to save money, almost 8%
of US adults (7.8%) did not take their medications as prescribed.77 Many of the patients
with CF can potentially fall under this category and may have to choose medications
based on the resources that they have access to. Not taking all the required medications
can lead to many complications for CF patients and higher healthcare utilization in the
future.

STUDY IMPLICATIONS
The present study was one of the first to assess the adherence to CFTR modulator
therapies in addition to reporting the costs of CFTR modulator therapies and medications
for comorbid conditions. The study findings have implications to all the stakeholders
including patients, specialty pharmacy, and payers.

Implications to the patients
The study provided data on discontinuation, missing doses and adverse events
associated with CFTR modulator therapies. It can assist patients and their caregivers to
initiate a conversation with their primary care physicians or any patient care coordinators
regarding issues with medications. Timely intervention can assist patients in being
adherent to the therapy and decrease complications thereby improving symptom
management and also quality of life. The study findings can also help patient is the
understanding their co-pay which can aid the patients and their caregivers in selecting the
insurance plan and its medication coverage policies.
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Implications to AllianceRx Walgreens Specialty Pharmacy
The study findings support the observation that patients enrolled in the CF
program at AllianceRx Walgreens specialty pharmacy are adherent to their therapies. The
reminders and follow ups initiated by the pharmacy are assisting patients in being
adherent to their therapy. Understanding the reasons for missing doses and
discontinuation from patients helps the pharmacy tailor their discussions with patients,
mostly at an early stage. Additionally, understanding the utilization of other medications
(other than CFTR modulator therapies) can help the pharmacy in working with patients
and payers to provide the best possible CF treatment plan. It is important to note that this
high adherence for CFTR modulator therapies may not be true for retail pharmacy stores
and/or other specialty pharmacies.

Implications to the payers
Patients enrolled in AllianceRx Walgreens specialty pharmacy demonstrated
higher adherence rates to CFTR regimen. In the long run, adherent patients have been
shown to have lower complications resulting in lower healthcare utilizations, which helps
both managed care organizations and payers such as Medicare and Medicaid.
The payers can also benefit from the findings on average co-pay difference
between primary and secondary insurances, and commercial and government insurances.
Since patients can compare the copay for these medications while choosing the plans, the
payers can use the results from this study to competitively price their co-pay for CFTR
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modulator therapies which can support the enrollment of higher number of CF patients in
their plan. Additionally, the study provides payers with the current landscape regarding
the utilization of the therapeutic class of medications used along with CFTR modulator
therapies. The payers can tailor plans and provide incentives or discounts to ease the
burden related to all the medications on the patient.

LIMITATIONS OF THE STUDY
Both phases of the study have some limitations, and these are discussed in the following
section. These limitations need to be considered before deriving inferences from the
reported results.

Part I
The limitations associated with any retrospective database are applicable to this
study. Some of these limitations include retrospective nature of the data, whose quality
may be limited by systematic or recorder bias, data coding-recoding errors, and
incomplete data. First, the last refill was used for all patients to describe the patient
population information. There may be instances where the patient characteristics such as
residence and co-morbidities could have changed after the last refill and this information
was not collected as the patients were no longer enrolled with AllianceRx Walgreens
specialty pharmacy. Hence, there was no way to account for such discrepancy in this
study. Second, self-reported data was analyzed to identify the responses such as
discontinuation and adverse events. These responses could be affected by social
desirability bias as patients may not want to be seen as non-compliant in front of their
PCC. Additionally, the questions used a recall period of 28 days, which may be subject to
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recall bias. As self-reported data largely depends on patient’s willingness to share the
details, patients could have opted out it which could have led to either underreporting of
some of the responses
Medication adherence was measured through pharmacy refill data. Although PDC
is an effective method, it assumes that availability and possession of medication by the
patient corresponds to the patient actually taking the medication. Thus, adherence
measurement should be viewed as an estimate, rather than as true results. Medication
adherence in our study was extremely high. AllianceRx Walgreens specialty pharmacy
conducts rigorous adherence counseling for its patients and these results may not be
generalizable to patients using CFTR modulator therapies through another specialty
pharmacy or retail pharmacies.

Part II
Similar limitations of a retrospective study were also applied to this part.
Specialty pharmacy spending was calculated using WAC from publicly available Red
Book. This might not represent the actual spending of the spending pharmacy as price of
the CFTR modulator therapy would be dependent on the contracts between AllianceRx
Walgreens specialty pharmacy and the manufacturer. Given the lack of this information
due to confidentiality agreement, we did not determine the real spending of the specialty
pharmacy. Also, this result is specific to AllianceRx Walgreens specialty pharmacy and a
similar trend in the spending can’t be generalized for other specialty pharmacies.
Self-reports could be impacted by recall bias and social desirability bias. Patients
might forget the medication name while reporting or confuse one medication for another
leading to overreporting or underreporting of medications. There is a possibility that
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patients might be on some of those medications only for a limited duration and then may
either switch or discontinue them. There is no way to capture this data. A wide range of
costs were also calculated from the Red Book based on certain assumptions as brand
name, package size and daily dosing of the medications were not reported in the data.
Thus, a single quantifiable value was not obtained for the medications included in the
data and instead a range was reported.

RECOMMENDATIONS FOR FUTURE RESEARCH
This study showed that patients enrolled in AllianceRx Walgreens specialty
pharmacy are extremely adherent to the CFTR modulator therapies. However, further
studies should aim to compare the adherence rates of patients enrolled with AllianceRx
Walgreens specialty pharmacy to patients enrolled in other specialty pharmacies. This
will help in providing scientific evidence in relation to the CF Program at AllianceRx
Walgreens specialty pharmacy. Additionally, a longitudinal study using administrative
claims data could be conducted to observe the healthcare utilization of patients’ adherent
on CFTR modulator therapies in comparison to those who aren’t. Another area to explore
could be to quantify the economic burden of different medications used in the treatment
of CF to a single numeric value using claims and pharmacy records. This will help in
providing a detailed list of the burden associated with the utilization of different
therapeutic classes of medications. The systematic review also highlighted that none of
the studies conducted in the US estimated the caregiver burden associated with CF.
Hence, both quantitative and qualitative methodologies could be employed to study the
same.
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APPENDIX I
Search Strategy for PubMed
("Cystic Fibrosis"[MESH] OR "Cystic Fibrosis"[tiab] OR "Cystic Fibrosis"[ot] OR
"Mucoviscidosis”[tiab] OR “Mucoviscidosis"[ot])
AND
(“economics”[MeSH] OR "economics" [Subheading] OR "economic"[tiab] OR
“economic”[ot] OR "economics"[tiab] OR “economics”[ot] OR "Costs and Cost
Analysis"[Mesh] OR “cost of illness”[MeSH] OR “cost of illness”[tiab] OR “cost of
illness”[ot] OR “cost of disease”[tiab] OR “cost of disease”[ot] OR “cost of
sickness”[tiab] OR “cost of sickness”[ot] OR "Health Care Costs"[Mesh] OR “healthcare
costs”[tiab] OR “healthcare costs”[ot] OR “healthcare expenditure”[tiab] OR “healthcare
expenditure”[ot] OR “healthcare utilization”[tiab] OR “health care utilization”[ot] OR
“health care costs”[tiab] OR “health care costs”[ot] OR “health care expenditure”[tiab]
OR “health care expenditure”[ot] OR “health care utilization”[tiab] OR “health care
utilization”[ot] OR “direct service costs”[MeSH] OR “direct service cost”[tiab] OR
“direct service cost”[ot] OR “direct service costs”[tiab] OR “direct service costs”[ot] OR
“hospital cost”[tiab] OR “hospital cost”[ot] OR “hospital costs”[MeSH] OR “hospital
costs”[tiab] OR “hospital costs”[ot] OR “hospitalization cost”[tiab] OR “hospitalization
cost”[ot] OR “hospitalization costs”[tiab] OR “hospitalization costs”[ot] OR “drug
cost”[tiab] OR “drug cost”[ot] OR “drug costs”[MeSH] OR “drug costs”[tiab] OR “drug
costs”[ot] OR "economic burden"[tiab] OR "economic burden"[ot] OR "economic
burdens"[tiab] OR "economic burdens"[ot] OR “economic impact”[tiab] OR “economic
impact”[ot] OR “economic impacts”[tiab] OR “economic impacts”[ot] OR “economic
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cost”[tiab] OR “economic cost”[ot] OR “economic costs”[tiab] OR “economic costs”[ot]
OR “economic analyses”[tiab] OR “economic analyses”[ot] OR “economic
analysis”[tiab] OR “economic analysis”[ot] OR “economic consequence”[tiab] OR
“economic consequence”[ot] OR “economic consequences”[tiab] OR “economic
consequences”[ot] OR “economic implication”[tiab] OR “economic implication”[ot] OR
“economic implications”[tiab] OR “economic implications”[ot] OR “medical
expenditure”[tiab] OR “medical expenditure”[ot] OR “medical expenditures”[tiab] OR
“medical expenditures”[ot])

Search Strategy for Scopus
(INDEXTERMS(“Cystic Fibrosis”) OR TITLE-ABS-KEY(“Cystic Fibrosis”) OR
TITLE-ABS-KEY(“Mucoviscidosis”))
AND
(INDEXTERMS(“Economics”) OR TITLE-ABS-KEY(“economic*”) OR
INDEXTERMS(“Costs and cost analysis”) OR
INDEXTERMS(“cost of illness”) OR TITLE-ABS-KEY(“cost of disease”) OR TITLEABS-KEY(“cost of illness”) OR INDEXTERMS(“health care costs”) OR TITLE-ABSKEY(“cost of sickness”) OR TITLE-ABS-KEY(“Claim*”) OR TITLE-ABSKEY(“health care expenditure*”) OR TITLE-ABS-KEY(“healthcare expenditure*”) OR
TITLE-ABS-KEY(“health care utilization”) OR TITLE-ABS-KEY(“healthcare
utilization”) OR TITLE-ABS-KEY(“health care cost*”) OR TITLE-ABSKEY(“healthcare cost*”) OR INDEXTERMS(“direct service costs”) OR TITLE-ABSKEY(“direct service cost*”) OR TITLE-ABS-KEY(“hospital cost*”) OR
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INDEXTERMS(“hospital costs”) OR TITLE-ABS-KEY(“hospitalization cost*”) OR
TITLE-ABS-KEY(“drug cost*”) OR TITLE-ABS-KEY(“economic burden*”) OR
TITLE-ABS-KEY(“economic impact*”) OR TITLE-ABS-KEY(“economic cost*”) OR
TITLE-ABS-KEY(“economic analysis”) OR TITLE-ABS-KEY(“economic analyses”)
OR TITLE-ABS-KEY(“economic consequence*”) OR TITLE-ABS-KEY(“economic
implication*”) OR TITLE-ABS-KEY(“medical expenditure*”))
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APPENDIX II
Code for objective 1
/********************
Code for demographics
By Zumi Mehta
*********************/
LIBNAME WGD "/folders/myshortcuts/Walgreens_Data";
RUN;
FILENAME DMO '/folders/myshortcuts/Walgreens_Data/Clinical_Research_SM6 Data
- DEIDv1 PDC Calculations 2.xlsx';
PROC IMPORT DATAFILE=DMO
DBMS=XLSX
OUT=WORK.Demo1;
sheet = "Last Fill";
GETNAMES=YES;
RUN;
data demo1;
set demo1;
Fill_date1 =input(fill_date,anydtdte32.);
format Fill_date1 DATE9.;
IF DRUG_NAME="ORKAMBI 100-125MG GRAN(56=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 100-125MG TAB (112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 100-125MG TAB(112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 150-188MG GRAN(56=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 200-125MG TAB (112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 200-125MG TAB(112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="KALYDECO 150MG (14 TAB/CARD)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO 150MG TAB" THEN DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO 150MG TAB (56=1BOX)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO ORAL GRAN 50MG (56=1)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO ORAL GRAN 75MG (56=1)" THEN
DRGNAME="KALYDECO";
103

IF DRUG_NAME="SYMDEKO 100-150MG TAB(56=1BOX)" THEN
DRGNAME="SYMDEKO";
IF DRUG_NAME="SYMDEKO 100MG/150MG-150MG TAB" THEN
DRGNAME="SYMDEKO";
run;
proc contents data=work.Demo1 varnum;
run;
data demo1;
set demo1;
Fill_date1 =input(fill_date,anydtdte32.);
format Fill_date1 mmddyy10.;
run;
data demo2;
set demo1;
where Patient_age>=18;
run;
proc univariate data=demo2;
var Patient_age;
run;
proc freq data= demo2;
tables Patient_gender Patient_state drgname primary_payer_type
Primary_Payer_Type*Secondary_Payer_Type;
run;
proc univariate data=demo1;
var Patient_age ;
run;
proc freq data=demo1;
table Drug_name ;
run;
proc freq data=demo1;
table Primary_Payer_Type ;
run;
proc freq data=demo1;
table Secondary_Payer_Type;
run;
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proc freq data=demo2;
table Primary_Payer_Type*Secondary_Payer_Type;
run;
proc freq data= demo2;
table Primary_Payer_Type;
where Secondary_Payer_Type=" ";
run;
data demo1;
SET demo1;
rename Patient__=PatientID;
run;
options missing = ' ';
data demo2;
set demo1;
if missing(cats(of _all_)) then delete;
run;
proc freq data=demo2;
tables Patient_Gender;
where .z<fill_date1<'01Jan2016'd;
run;
proc freq data=demo2;
tables Patient_Gender;
where '31Dec2015'd<fill_date1<'01Jan2017'd;
run;
proc freq data=demo2;
tables Patient_Gender;
where '31Dec2016'd<fill_date1<'01Jan2018'd;
run;
proc freq data=demo2;
tables Patient_Gender;
where fill_date1>='01Jan2018'd;
run;
/*the addition of all of these is not adding up to 4444 so I am trying to create a new
variable of year*/
data demo3;
set demo2;
fillyear=Year(Fill_date1);
run;
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proc freq data=demo3;
table fillyear;
run;
/*deleting people with no secondary payer*/
options missing = ' ';
data del;
set demo2;
if missing(cats(of Secondary_payer_type)) then delete;
run;
/********************
Code for allergy
By Zumi Mehta
*********************/
LIBNAME ALL "/folders/myshortcuts/Walgreens_Data";
RUN;
FILENAME ALGg '/folders/myshortcuts/Walgreens_Data/Allergy.xlsx';
PROC IMPORT DATAFILE=ALGg
DBMS=XLSX
OUT=WORK.alggg;
GETNAMES=YES;
RUN;
proc contents data=work.alggg varnum;
run;
proc freq data=alggg;
table Allergy1;
run;

Code for objective 2
/*************************
CODE TO EXTRACT AND ANALYSE DATA
REGARDING REASONS AND SIDEFFECTS
DATE- 3/27/19
BY: ZUMI MEHTA
***************************/
LIBNAME RS "/folders/myshortcuts/Walgreens_Data";
RUN;
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/*IMPORTING THE DATA FILE Clinical_Research_SM6 Data*/
FILENAME SE1 '/folders/myshortcuts/Walgreens_Data/SR2 _2012-2018 DEIDv1.xlsx';
PROC IMPORT OUT=WORK.RS1
DATAFILE=SE1
DBMS=XLSX;
sheet ="sr2new";
GETNAMES=YES;
RUN;
PROC contents data=RS1 varnum;
run;
proc freq data=rs1;
where DISCONTINUED_MEDICATION_QTS_ID=8248;
tables discontinued_medication_response;
run;
proc freq data=rs1;
where DISCONTINUED_MEDICATION_QTS_ID=8249;
tables discontinued_medication_response;
run;
proc freq data=rs1;
where DISCONTINUED_MEDICATION_QTS_ID=19317;
tables discontinued_medication_response;
run;
proc freq data=rs1;
where SIDE_EFFECTS_REASON_QTS_ID=8040;
tables SIDE_EFFECTS_REASON_RESPONSE;
run;
proc freq data=rs1;
where SIDE_EFFECTS_REASON_QTS_ID=12694;
tables SIDE_EFFECTS_REASON_RESPONSE;
run;
proc freq data=rs1;
where SIDE_EFFECTS_REASON_QTS_ID=18576;
tables SIDE_EFFECTS_REASON_RESPONSE;
run;
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proc freq data=rs1;
where SIDE_EFFECTS_REASON_QTS_ID=19219;
tables SIDE_EFFECTS_REASON_RESPONSE;
run;
proc freq data=rs1;
where SIDE_EFFECTS_REASON_QTS_ID=19220;
tables SIDE_EFFECTS_REASON_RESPONSE;
run;
proc freq data=rs1;
where SIDE_EFFECTS_REASON_QTS_ID=19222;
tables SIDE_EFFECTS_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=8060;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=8061;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=12696;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=12697;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=18580;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=18581;
tables MISSED_DOSES_REASON_RESPONSE;
run;
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proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=19154;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=19155;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=19157;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where MISSED_DOSES_REASON_QTS_ID=19163;
tables MISSED_DOSES_REASON_RESPONSE;
run;
proc freq data=rs1;
where discontinued_medication_Question="(Do not read) Select medication that was
discontinued:";
tables discontinued_medication_response;
run;
proc freq data=rs1;
tables GENOTYPE_QUESTION GENOTYPE_RESPONSE
DISCONTINUED_MEDICATION_QTS_ID
DISCONTINUED_MEDICATION_QUESTION
DISCONTINUED_MEDICATION_RESPONSE
SIDE_EFFECTS_REASON_QUESTION SIDE_EFFECTS_REASON_RESPONSE;
run;
/*choosing data where we get information only about the discontinued medication*/
data o1b2 (where=(DISCONTINUED_MEDICATION_QTS_ID=8248 or
DISCONTINUED_MEDICATION_QTS_ID=19317));
set rs1;
run;

Code for Objective 3
/*************************************
Code on 03/12/2018
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PDC CALCULATIONS
BY: ZUMI MEHTA*/
LIBNAME CDCC "/folders/myshortcuts/Walgreens_Data";
RUN;
/*IMPORTING THE DATA FILE Clinical_Research_SM6 Data*/
FILENAME PG1 '/folders/myshortcuts/Walgreens_Data/Clinical_Research_SM6 Data DEIDv1 PDC Calculations 2.xlsx';
PROC IMPORT OUT=WORK.CPDC
DATAFILE=PG1
DBMS=XLSX;
sheet ="Page1_1";
GETNAMES=YES;
RUN;
PROC contents data=Cpdc;
run;
data cpdc;
set cpdc;
Fill_date1 =input(fill_date,anydtdte32.);
format Fill_date1 DATE9.;
IF DRUG_NAME="ORKAMBI 100-125MG GRAN(56=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 100-125MG TAB (112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 100-125MG TAB(112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 150-188MG GRAN(56=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 200-125MG TAB (112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 200-125MG TAB(112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="KALYDECO 150MG (14 TAB/CARD)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO 150MG TAB" THEN DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO 150MG TAB (56=1BOX)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO ORAL GRAN 50MG (56=1)" THEN
DRGNAME="KALYDECO";
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IF DRUG_NAME="KALYDECO ORAL GRAN 75MG (56=1)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="SYMDEKO 100-150MG TAB(56=1BOX)" THEN
DRGNAME="SYMDEKO";
IF DRUG_NAME="SYMDEKO 100MG/150MG-150MG TAB" THEN
DRGNAME="SYMDEKO";
run;
data cpdc;
SET cpdc;
rename Patient__=PatientID;
run;
proc freq data=cpdc;
tables Drug_name;
run;
data oney;
set cpdc;
where '31AUG2017'd < fill_date1;
run;
data l18;
set cpdc;
where Patient_age<18;
run;
data g18;
set cpdc;
where Patient_age>=18;
run;
data ol18;
set cpdc;
where Patient_age<18 and '31AUG2017'd < fill_date1;
run;
data og18;
set cpdc;
where Patient_age>=18 and '31AUG2017'd < fill_date1;
run;
data pcpdc;
set cpdc;
where Secondary_payer_type <> " ";
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run;
/*CALCULATING PDC*/
/*CREATING A MACRO*/
%MACRO MEDAD(lib=, datain=, dataout=, id=, filldt=, daysup=,
class=, ibendt=., fp=., type=, decpct=2, debug=N);
%let debug=%upcase(&debug);
%if (&debug=Y) %then %do;
options mprint mtrace macrogen notes linesize=132 ps=58; %end;
%else %do;
options nonotes nomprint nomacrogen nomtrace nosymbolgen nomlogic
linesize=132 ps=58; %end;
%if %sysfunc(exist(&lib..&datain.))=0 %then %do;
%put ERROR: DATA SET &datain. DOES NOT EXIST.;
%put ERROR- MACRO WILL TERMINATE NOW.;
%return;
%end;
%if (&decpct=4) %then %let decpct=0.0001;
%if (&decpct=3) %then %let decpct=0.001;
%if (&decpct=2) %then %let decpct=0.01;
%if (&decpct=1) %then %let decpct=0.1;
%if (&decpct=) %then %let decpct=1;
/***Step 1***/
/***Remove duplicate dispense record***/
PROC SORT DATA=&lib..&datain. out=&datain._dedup; BY &id. &class.
&filldt.; RUN;
/***Identify first dispense record and last dispense record***/
PROC SQL;
CREATE TABLE RXCLM
AS SELECT &ID., &FILLDT., &CLASS.,
MIN(&FILLDT.) AS INDEX_DT FORMAT=MMDDYY10.,
MAX(&FILLDT.) AS LSTRX_DT FORMAT=MMDDYY10.,
&DAYSUP.
FROM &DATAIN._DEDUP
GROUP BY &ID., &CLASS.
ORDER BY &ID., &CLASS., &FILLDT.;
QUIT;
/***Step 2***/
/**Create a dataset that contains case with one dispense record only**/
DATA ONERX RXCLM1;
SET RXCLM END=EOF1;
BY &ID. &CLASS.;
IF FIRST.&CLASS. AND LAST.&CLASS. THEN OUTPUT ONERX;
ELSE OUTPUT RXCLM1;
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RUN;
/***Step 3***/
/**Create end date for each dispense record and for the end of study period**/
DATA MAXEND;
SET RXCLM1;
%IF &IBENDT ^=. %THEN %DO;
IB_END = (input("&IBENDT.",date9.)) ; /*Cross sectional*/
%END;
%ELSE %IF &FP.^=. %THEN %DO;
IB_END = INDEX_DT + &FP. -1;
%END;/*Longitudinal*/
FILL_END_DT = &FILLDT. +&DAYSUP. - 1 ;
END_DT=FILL_END_DT;
FORMAT END_DT IB_END MMDDYY10.;
RUN;
/***Step 4***/
/**Create macro for the earliest start date and latest end date**/
PROC SQL;
SELECT MIN(INDEX_DT), MAX(END_DT)
INTO :START, :TERM
FROM MAXEND;
QUIT;
/**Create dummy var to represent days in study period and flag dummy as 1
if it has drug avaiable**/
DATA AD_1;
ARRAY FLAG(&START. :&TERM. );
SET MAXEND;
BY &ID. &CLASS.;
DO I= &START. to &TERM.;
FLAG(I)=0;
END;
/* move through the days covered */
DO U=&FILLDT. to FILL_END_DT;
FLAG(U)=1;
END;
DROP I U;
RUN;
/***Step 5***/
%LET INTRL= %EVAL(&TERM. - &START. +1);
%PUT &INTRL;
/***Step 6***/
/***Summarize the flagged days in the last record of each class***/
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DATA AD_2;
DO UNTIL (LAST.&CLASS.);
SET AD_1;
BY &ID. &CLASS.;
ARRAY FLAG(&INTRL.) FLAG1-FLAG&INTRL.;
ARRAY SUMFLAG(&INTRL.);
DO I=1 TO &INTRL.;
SUMFLAG(I) = SUM(SUMFLAG(I), FLAG(I));
END;
END;
%IF %UPCASE(&TYPE)=PDC %THEN %DO;
DO U=1 TO &INTRL.;
IF SUMFLAG(U) GE 1 THEN SUMFLAG(U)=1; ELSE SUMFLAG(U)=0;
END;
%END;
DROP I FLAG:;
RUN;
/***Step 7***/
/**Adjust the end date based off the types of measurements***/
DATA &DATAOUT.;
SET AD_2;
ARRAY TAT(&INTRL.) SUMFLAG1 - SUMFLAG&INTRL.;
*--Interval based metric;
IF IB_END =. THEN &TYPE._1=.;
ELSE DO;
NUM1=0;
ARRAYEND=IB_END - &START. + 1;
DO H=1 TO ARRAYEND;
NUM1= TAT(H)+ NUM1;
END;
DENO1= IB_END - INDEX_DT +1;
&TYPE._1 = ROUND(MIN((NUM1/DENO1),1), &decpct.);
END;
/**Rx based including last refill**/
NUM2= SUM(OF SUMFLAG1-SUMFLAG&INTRL.);
DENO2=FILL_END_DT - INDEX_DT +1;
&TYPE._2 = ROUND(MIN((NUM2 /DENO2),1), &decpct.);
/**Rx based excluding last refill**/
NUM3= SUM(OF SUMFLAG1-SUMFLAG&INTRL.) - (&DAYSUP.);
DENO3= &FILLDT. - INDEX_DT;
&TYPE._3 = ROUND(MIN((NUM3 /DENO3),1), &decpct.);
KEEP &ID. &CLASS. &TYPE.: ;
FORMAT FILL_END_DT MMDDYY10.;
RUN;
%MEND;
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%MEDAD (lib=WORK, datain=cpdc, dataout=calpdc, id=PatientID, filldt=Fill_date1,
daysup=Day_supply,
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N);
%MEDAD (lib=WORK, datain=oney, dataout=oneypdc, id=PatientID, filldt=Fill_date1,
daysup=Day_supply,
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N);
%MEDAD (lib=WORK, datain=l18, dataout=l18pdc, id=PatientID, filldt=Fill_date1,
daysup=Day_supply,
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N);
%MEDAD (lib=WORK, datain=g18, dataout=g18pdc, id=PatientID, filldt=Fill_date1,
daysup=Day_supply,
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N);
%MEDAD (lib=WORK, datain=ol18, dataout=ol18pdc, id=PatientID, filldt=Fill_date1,
daysup=Day_supply,
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N);
%MEDAD (lib=WORK, datain=og18, dataout=og18pdc, id=PatientID, filldt=Fill_date1,
daysup=Day_supply,
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N);
%MEDAD (lib=WORK, datain=pcpdc, dataout=pcpdc1, id=PatientID, filldt=Fill_date1,
daysup=Day_supply,
class=Drgname, ibendt=31AUG2018, fp=., type=PDC, decpct=2, debug=N);
proc sql noprint;
create table temp as
select PATIENTID, count(*) as ct
from CalPdc
group by PATIENTID;
select max(ct) into :_mcount from temp;
quit;
proc univariate data=calpdc;
var PDC_2;
run;
proc univariate data=calpdc;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=calpdc;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=calpdc;
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var PDC_2;
where drgname= "ORKAMBI";
run;
proc univariate data=pcpdc1;
var PDC_2;
run;
proc univariate data=pcpdc1;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=pcpdc1;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=pcpdc1;
var PDC_2;
where drgname= "ORKAMBI";
run;
proc univariate data=oney;
var Fill_date1;
Format fill_date1 MMDDYY10.;
run;
proc univariate data=oneypdc;
var PDC_2;
run;
proc means data= oney maxdec=2;
var PDC_2;
run;
proc univariate data=oneypdc;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=oneypdc;
var PDC_2;
where drgname= "SYMDEKO";
run;
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proc univariate data=oneypdc;
var PDC_2;
where drgname= "ORKAMBI";
run;
proc univariate data=l18pdc;
var PDC_2;
run;
proc univariate data=l18pdc;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=l18pdc;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=l18pdc;
var PDC_2;
where drgname= "ORKAMBI";
run;
proc univariate data=g18pdc;
var PDC_2;
run;
proc univariate data=g18pdc;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=g18pdc;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=g18pdc;
var PDC_2;
where drgname= "ORKAMBI";
run;
proc freq data=calpdc;
table pdc_2;
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run;
data calpdc;
set calpdc;
run;
proc univariate data=ol18pdc;
var PDC_2;
run;
proc univariate data=ol18pdc;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=ol18pdc;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=ol18pdc;
var PDC_2;
where drgname= "ORKAMBI";
run;
proc univariate data=og18pdc;
var PDC_2;
run;
proc univariate data=og18pdc;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=og18pdc;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=og18pdc;
var PDC_2;
where drgname= "ORKAMBI";
run;
proc export data=calpdc
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OUTFILE="/folders/myshortcuts/Walgreens_Data/calpdc.xls"
DBMS=XLS REPLACE;
SHEET="calp";
run;
proc export data=oneypdc
OUTFILE="/folders/myshortcuts/Walgreens_Data/oneypdc.xls"
DBMS=XLS REPLACE;
SHEET="oney";
run;
data comp;
set oneypdc;
run;
proc freq data=comp noprint;
tables PatientID/ out=comp1 (Keep=PatientID count where=(count>1));
run;
proc print data=comp1;
run;
data compx;
set comp;
by PatientID;
if first.patientid and last.patientid then dup=0;
else dup=1;
if dup=1 then delete;
run;
proc univariate data=compx;
var PDC_2;
run;
proc univariate data=compx;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=compx;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=compx;
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var PDC_2;
where drgname= "ORKAMBI";
run;
data ocompx;
set ol18pdc;
by PatientID;
if first.patientid and last.patientid then dup=0;
else dup=1;
if dup=1 then delete;
run;
proc univariate data=ocompx;
var PDC_2;
run;
proc univariate data=ocompx;
var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=ocompx;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=ocompx;
var PDC_2;
where drgname= "ORKAMBI";
run;
data gcompx;
set og18pdc;
by PatientID;
if first.patientid and last.patientid then dup=0;
else dup=1;
if dup=1 then delete;
run;
proc univariate data=gcompx;
var PDC_2;
run;
proc univariate data=gcompx;
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var PDC_2;
where drgname= "KALYDEC";
run;
proc univariate data=gcompx;
var PDC_2;
where drgname= "SYMDEKO";
run;
proc univariate data=gcompx;
var PDC_2;
where drgname= "ORKAMBI";
run;

Code for objective 4
/***********************
Co-pay Calculations
Thesis
By: Zumi Mehta
date- 5/14/19
*************************/
LIBNAME COPAY "/folders/myshortcuts/Walgreens_Data";
RUN;
/*IMPORTING THE DATA FILE Clinical_Research_SM6 Data*/
FILENAME COP '/folders/myshortcuts/Walgreens_Data/Clinical_Research_SM6 Data DEIDv1 PDC Calculations 2.xlsx';
PROC IMPORT OUT=WORK.COPA
DATAFILE=COP
DBMS=XLSX;
sheet ="Page1_1";
GETNAMES=YES;
RUN;
PROC contents data=COPA;
run;
data cops;
set copa;
Fill_date1 =input(fill_date,anydtdte32.);
format Fill_date1 DATE9.;
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IF DRUG_NAME="ORKAMBI 100-125MG GRAN(56=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 100-125MG TAB (112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 100-125MG TAB(112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 150-188MG GRAN(56=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 200-125MG TAB (112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="ORKAMBI 200-125MG TAB(112=1BX)" THEN
DRGNAME="ORKAMBI";
IF DRUG_NAME="KALYDECO 150MG (14 TAB/CARD)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO 150MG TAB" THEN DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO 150MG TAB (56=1BOX)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO ORAL GRAN 50MG (56=1)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="KALYDECO ORAL GRAN 75MG (56=1)" THEN
DRGNAME="KALYDECO";
IF DRUG_NAME="SYMDEKO 100-150MG TAB(56=1BOX)" THEN
DRGNAME="SYMDEKO";
IF DRUG_NAME="SYMDEKO 100MG/150MG-150MG TAB" THEN
DRGNAME="SYMDEKO";
run;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI";
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC";
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO";
RUN;
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PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=COPs;
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VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=COPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
data onlyp;
set cops;
where Secondary_Payer_Type=" ";
run;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
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where drgname= "ORKAMBI" and Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where Fill_date1> '31dec2017'd and Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and Fill_date1> '31dec2017'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and Fill_date1> '31dec2017'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and Fill_date1> '31dec2017'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where '31dec2016'd<Fill_date1<'1jan2018'd and Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2016'd<Fill_date1<'1jan2018'd and
Primary_Payer_Type="Commercial";
RUN;
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PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and '31dec2016'd<Fill_date1<'1jan2018'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2016'd<Fill_date1<'1jan2018'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where '31dec2015'd<Fill_date1<'1jan2017'd and Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2015'd<Fill_date1<'1jan2017'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and '31dec2015'd<Fill_date1<'1jan2017'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2015'd<Fill_date1<'1jan2017'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where '31dec2014'd<Fill_date1<'1jan2016'd and Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2014'd<Fill_date1<'1jan2016'd and
Primary_Payer_Type="Commercial";
RUN;
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PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and '31dec2014'd<Fill_date1<'1jan2016'd and
Primary_Payer_Type="Commercial";
RUN;
PROC UNIVARIATE DATA=onlyp;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2014'd<Fill_date1<'1jan2016'd and
Primary_Payer_Type="Commercial";
RUN;
data pscops;
set cops;
where Secondary_Payer_Type<>" " and Primary_Payer_Type="Commercial" and
Secondary_Payer_Type="Government";
run;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC";
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI";
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO";
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
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VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
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where drgname= "ORKAMBI" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "KALYDEC" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "ORKAMBI" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR PRIMARY_COPAY;
where drgname= "SYMDEKO" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;

PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "KALYDEC";
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "ORKAMBI";
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
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where drgname= "SYMDEKO";
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "KALYDEC" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "ORKAMBI" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "SYMDEKO" and Fill_date1> '31dec2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "KALYDEC" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "ORKAMBI" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "SYMDEKO" and '31dec2016'd<Fill_date1<'1jan2018'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where '31dec2015'd<Fill_date1<'1jan2017'd;
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RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "KALYDEC" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "ORKAMBI" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "SYMDEKO" and '31dec2015'd<Fill_date1<'1jan2017'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "KALYDEC" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "ORKAMBI" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
PROC UNIVARIATE DATA=psCOPs;
VAR SECONDARY_COPAY;
where drgname= "SYMDEKO" and '31dec2014'd<Fill_date1<'1jan2016'd;
RUN;
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APPENDIX III
List of all co-morbidities
Disease

Frequency (n) Percent (%)

Endocrine, nutritional and metabolic diseases, and
immunity disorders, diseases of the blood and bloodforming organs
Diseases of the respiratory system
Infectious and parasitic diseases
Diseases of the digestive system
Symptoms, signs, and ill-defined conditions
Diseases of the nervous system and sense organs
Congenital anomalies
Diseases of the genitourinary system
Diseases of the skin and subcutaneous tissue
Mental disorders
Diseases of the musculoskeletal system and
connective tissue

4770

56.83

1143
563
496
375
252
187
111
111
105
75

13.62
6.71
5.91
4.47
3.00
2.23
1.32
1.32
1.25
0.89

Diseases of the circulatory system
Injury and poisoning
Certain conditions originating in the perinatal period
Neoplasms
Complications of pregnancy, childbirth, and the
puerperium

71
59
41
18
16

0.85
0.70
0.49
0.21
0.19
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APPENDIX IV
List of all reported allergies
Allergy
No Known Drug Allergy
Allergy History Not Known
Sulfa Antibiotics
Penicillins
No Known Environmental Allergy
Sulfonamide Derivatives
Cephalosporins
No Known Food Allergy
Vancomycin
Latex
Adhesive
Hydrocodone
Peanut-containing Drug Products
Sulfa Drugs Cross Reactors
Morphine and Related
Quinolones
Streptokinases
Gluten
Rifamycins
Shellfish-derived Products
Eggs or Egg-derived Products
Macrolides and Ketolides
Plastic tape
Spironolactone
Nsaids
Paper tape
Aminoglycosides
Milk-related Compounds
No Known Latex Allergy
Iodides
Lactose Intolerance (GI)
Red Dye
Clindamycin/Lincomycin
Soybean-containing Drug Products

Frequency (n)
3016
365
219
183
137
111
64
47
38
34
32
28
26
23
18
18
13
11
11
11
10
10
10
8
7
7
6
6
6
5
5
5
4
4
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Percent (%)
66.07
8
4.8
4.01
3
2.43
1.4
1.03
0.83
0.74
0.7
0.61
0.57
0.5
0.39
0.39
0.28
0.24
0.24
0.24
0.22
0.22
0.22
0.18
0.15
0.15
0.13
0.13
0.13
0.11
0.11
0.11
0.09
0.09

Antihistamines
Egg
Fish-derived Products
Iodinated Diagnostic Agents
Salicylates
Tetracyclines & Related
Allopurinol
Aztreonam
Barbiturates
Corn-containing Products
Nitrofuran Derivatives
Silver
Statins
Sulfites
Uncoded Nonscreenable Allergen
Chlorpheniramine-type
Loratadine-type
ACE Inhibitors
Acetaminophen
Alpha Blocker Quinazolines
Aminoquinolines
Beta Adrenergic Blockers
Blue Dyes (Parenteral)
Clavulanic Acid
Corticosteroids
Dienestrol
Ethylenediamine
Glutethimides
Green Dyes
Guaifenesin & Derivatives
IV Dye
Immune Globulins
Insulins
Janumet
Nuts
PABA Derivatives
Peanuts
Pork-derived Products
Strawberries

3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

0.07
0.07
0.07
0.07
0.07
0.07
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
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Streptomycin
Succinamides
Tegaderm
Tetanus Toxoids
Thimerosal
Tramadol
Trimethoprim

1
1
1
1
1
1
1

0.02
0.02
0.02
0.02
0.02
0.02
0.02
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